Hypertension: New Frontiers—A Textbook of Cardiology Praveen Chandra, Navin C Nanda, HK Chopra, GS Wander, Jagat Narula, CN Manjunath
INDEX
Page numbers followed by b refer to box, f refer to figure, fc refer to flowchart, and t refer to table.
A
Abdominal aorta 146, 225f, 229, 589f
aneurysmal dilatation of 320f
infrarenal 571
lesions of 145, 149
Abdominal distention 166
Abdominal endovascular aortic repair 226
Abruptio placentae 873
Acceleration time 590
Accentuated arteriolar light reflex 102f
Accredited Social Health Activist 3, 202
Acebutolol 697
Acetazolamide 31
Acetylcholine 142
Activated T-cells, nuclear factor of 175f
Acute aortic conditions, symptoms in 241
Acute aortic dissection 218fc, 229t, 230b, 795
management strategies for 242
Acute aortic syndromes 224, 230t, 318, 563, 572, 577
Acute cardiomyopathy 495
Acute coronary syndrome 388, 530, 605, 606, 609612, 616, 619, 816
Acute decompensated heart failure 523, 529, 913
Acute Decompensated Heart Failure
device therapy for 913
National Registry 494
Acute heart failure 474f, 495, 524, 529, 610
managing 913f
Acute left ventricular failure 3
Acute myocardial infarction 495, 606, 609, 616, 619, 815
valsartan in 606
Acute stroke, treatment of 555
Adenoma 169
Adenosine 79
triphosphate 79, 152, 485f, 619, 624, 886, 906
Adipokines
functions of 860t
role of 860
Adrenal cortical adenoma 307
Adrenal diseases 23
Adrenal gland 121f, 306, 307, 310f, 311f
right 307
Adrenal hyperplasia 311f
bilateral 164, 307
idiopathic 164, 169, 169t
primary 171
Adrenal incidentaloma 167
Adrenal lesions
benign 307
malignant 307
Adrenal nervous system 120
Adrenal venous sampling 170
Adrenal zona glomerulosa cells 165
Adrenalectomy 308
unilateral 309
Adrenocorticotropic hormone 63, 68, 306, 308
Advanced echocardiographic assessment 389
Advanced glycation end products 39, 887, 891
Advanced strain imaging echocardiography 369
Adverse cardiovascular events, major 275, 472, 612, 623
Adverse drug reaction 518
Aerobic exercise 78, 79
African American Study of Kidney Disease 500
Air pollution 95, 96
types of 95
Aircraft noise 107
Alanine transaminase 508, 872
Albumin-creatinine ratio 157, 159, 297, 871
Albuminuria 39t, 42
management of 40
screening of 39
Alcohol 19, 198, 722, 872
abuse 914
consumption 802
control of 543
Aldosterone 164, 818, 850
antagonists 607, 696, 747, 777, 818, 845, 942
diurnal rhythm of 168
effects, molecular mechanism of 164
escape 775
level 171
measuring 167
mediates reabsorption 25
producing adenoma 163, 164
production, regulation of 165
receptor
antagonists 620
blockade 942
role of 771
to-renin ratios 422
Aldosteronism, metabolic complications in primary 163t
Aldosteronomas, typical 171
Alkaline phosphatase 508
Allograft 591
kidney 591t
renal vasculature of 316f
Allopurinol 155
Alpha-adrenergic
agonists 874
receptor, types of 732
Alpha-adrenoceptor antagonists 821
Alpha-blockers 75, 171, 500, 731, 735, 736t, 834, 879
classical triads of 731, 731fc
role of 733
Alprazolam 623
Alprostadil 377, 380
Alzheimer's dementia 781
development of 949
Alzheimer's disease 173
Ambient air pollution 95
Ambulatory blood pressure 133, 270f, 412
collaboration 282
measurement 12, 127, 263
monitor tracings, twenty-four-hour 271f
monitoring 11, 30, 50, 96, 134, 157, 180, 258t, 262, 269f271f, 273t, 276, 294, 509t, 654, 664, 682, 691, 693t, 711, 821, 832, 849, 865, 901, 907, 936, 951
advantages of 273
emergence of 11
indications of 269, 682
limitations of 273
studies 96
technical aspects of 268
recording, twenty-four-hour 271f
American Academy of Family Physicians 56, 754
American College of Cardiology 8, 46, 4952, 56, 115, 127, 132, 153, 189, 191, 210, 220, 306, 398, 440, 472, 487, 526, 567, 606, 618, 644, 645f, 679, 694, 698, 754, 951
American College of Physicians 56, 754
American College of Sport Medicine 80
American Diabetes Association 39, 46, 210
American Geriatrics Society 46
American Heart Association 8, 46, 4952, 56, 115, 127, 132, 189, 191, 210, 217fc, 220, 279, 298, 306, 398, 420, 439, 487, 526, 574, 606, 616, 626, 645f, 679, 690, 694, 754, 777, 840, 951
Blood Pressure Guideline 644
American Society of Anesthesiologists 189, 191
American Society of Echocardiography 351, 446
American Society of Hypertension 10, 46, 748
Amiloride 414, 739, 742, 746
Amlodipine 161, 277, 284, 723, 724, 743, 746, 789
Amphetamine 906, 946
Amyloidosis, cardiac 444
Anabolic steroids 802
Ancient Indian System of Medicine 7
Androgens 850
Aneroid devices 693
Anesthesia considerations, perioperative 623
Aneurysm 222
Angina 469
Angiography
invasive 327
using digital subtraction technique 147
Angiotensin receptor antagonists 696
Angiotensin receptor blockers 41, 51, 75, 84, 135, 148, 171, 185, 234f, 283, 326, 421, 437, 474f, 486f, 491, 498, 517, 522, 529, 543, 543f, 545f, 606, 616, 631, 634, 647, 664, 699, 721, 726, 732, 743, 748, 757, 769, 780, 790, 817, 834, 845, 860, 870, 905, 936, 952, 955
effect of 419
inhibition, mechanism of 726
therapy 247, 326
Angiotensin receptor neprilysin inhibitor 283, 480, 512, 513, 517, 519, 527t, 533, 632, 779, 941, 946, 947, 947fc, 948, 949fc
clinical applications of 528
clinical trials of 523
role of 480
Angiotensin-converting enzyme 24f, 25, 28, 74, 84, 152, 173, 191, 234f, 252, 417, 474f, 475f, 486f, 498, 598, 610, 631, 645f, 689, 728, 741, 744, 757, 769, 775, 788, 794, 801, 825f, 834, 851, 870, 879, 887, 905, 936, 952
gene polymorphism 173
inhibitor 41, 42, 51, 59, 75, 84, 141, 160f, 179, 185, 225, 247, 284, 326, 380, 437, 499, 517, 527, 543, 543f, 599, 606, 619, 634, 664, 670, 696, 723, 731, 747, 779, 817, 824, 834, 860, 946
Angiotensinogen 899
Anglo-Scandinavian Cardiac Outcomes Trial 59, 744
Ankle-brachial index 296, 680
Ankylosing spondylitis 563
Annoyance 107
reaction 107
Annual health survey 201
Annual incidence rate 553
Annular mitral velocity, measurement of 360f
Annuloaortic ectasia 145
Antagonist oral anticoagulants 796
Antiadrenergic drugs 789
Antiarrhythmic drug therapy 438
Anticoagulation therapy 607
Anticonvulsant management 880
Antidiabetic medications 620
Antidiuretic hormone 23, 24f, 899
Antihypertension therapy 180
Antihypertensive 723
agents 606, 753, 762, 785
drugs 54t, 111, 171, 181, 218, 265, 375, 380, 441, 670, 731, 752, 846t, 852t
effect of 181t
side effects of 857
three first-line 946
effects 697fc, 947
medications 74, 299, 353, 385, 769, 801, 817
initiation of 834
pharmacologic therapy 873
regimens 277
choice of 664
strategies 233
therapy 290, 292, 454, 472t, 535, 760fc, 914
treatment 366, 671, 743t, 744t
meta-analysis of 544
monitoring of 284
Anti-inflammatory drugs 742
Antioxidant defense 140
Anti-Parkinson's drugs 394
Antipsychotics 821
Anuria 873
Anxiety 625, 792
high levels of 64
role of 64
shortness of 792
Aorta 557
aneurysmal dilatation of 319f
arch of 318f
ascending 146, 226, 561f, 563f, 569f, 921f
assessment of 224, 404, 559
balloon angioplasty of 149
coarctation of 216, 295, 315, 341f, 564, 565f, 568, 831, 836f
descending 228, 564f, 836f
dissection of 562f
echocardiographic
evaluation of 559
imaging of 559
functional assessment of 578
hybrid repair of 227f, 228f
juxtadiaphragmatic 570f
pathology of 562
recoils 289
renal anastomosis 150
three layers of 214f
traumatic injury to 564
Aortic aneurysm 241
ascending 563f
infrarenal 596
Aortic angiogram 837f
Aortic arch 145, 227
branches of 146
interrupted 569
Aortic assessment 575
Aortic atheroma 564
grading of 564t
Aortic baroreceptors 898
Aortic bifurcation, slightly above 898
Aortic branches 145, 318
Aortic changes, pathophysiology of 574
Aortic chemoreceptors 898
Aortic coarctation 306, 567, 576, 847
Aortic compliance 578
Aortic complications 318
Aortic computed tomography 567
angiography
role of 568b
technique 567
Aortic damage 793
Aortic diseases 568
family history of 230
Aortic dissection 214, 216, 223, 229, 230, 357, 560, 563, 563t, 572, 577f, 585
classical triads of 215f, 240
complicated type B 231
extension of 600
incidence of 215
management of 217fc
mechanism of 216b
prevalence of 215
prognosis of 241
type
A 230
B 231
uncomplicated type B 231
Aortic involvement 242
Aortic leaflet 427
calcification 427
Aortic measurements 560f
Aortic media abnormalities 216
Aortic morphology 577
Aortic plaque imaging 575
Aortic pressure 428
Aortic pulse wave velocity 578
Aortic regurgitation 145, 216, 217, 403, 642, 920
Aortic root
diameters 462
dilatation 462
Aortic stenosis 372, 426
moderate 372
severity 428t
indices of 428
Aortic stiffness 561, 578, 579
measurement of 561
Aortic ulcer, penetrating 230, 564, 564f
Aortic valve 428
annulus 560f
area 427, 428
calcification 427f
closure 454
replacement 216
Aortic wall 216
Aortitis 567
Aortoarteritis 145, 148, 150, 315, 318f, 837f
disease, nonspecific 145, 570
Aortography 242
Aortopathy 571
uncontrolled 222
Apararenone 772
Apical ballooning syndrome 388
Apixaban 797, 798
Apnea-hypopnea index 27, 33
Arachidonic acid, Cyp450-derived metabolites of 121
Arginine
metabolite asymmetric dimethylarginine 111
potential future role of 887
Arrhythmia 301, 427, 443, 453, 745
cardiac 436
pathogenesis of 631
type of 438
Arterial dissection 240, 585, 596
Arterial embolus 585
Arterial hypertension 23, 110, 150, 275, 370, 454, 538, 574, 762, 815, 860, 936
classical triads of 538t
pathogenesis of 146
Arterial occlusions 103
Arterial pressure, measurement of mean 879
Arterial pulse wave velocity 649
Arterial stiffness 394, 404, 635, 691
Arteriogenic dysfunction 376
Arteriogram abnormality 146
Arteriosclerosis 561
Arteriovenous shunt 635
role of 637
Artery
brachial 265
direction of 379
femoral 921f
small 280
stiffness, measurement of large 650f
Arthralgia 146
Artificial heart, total 233
Artificial intelligence 329331
application of 812
role of 813
Artificial neural network 330, 330f
Asian hypertension 948
Asia-Pacific Society of Hypertension 8
Aspartate transaminase 508
Aspirin, low-dose 879
Asthma 95
Asymptomatic organ damage, causes of 383
Atenolol 75, 697, 699, 712, 713, 724
Atheroembolic disease 247
Atheroma 564f
Atheromatous disease 319f
Atherosclerosis 25, 380, 431, 497, 571, 585, 591, 596, 815, 822
development of 815
Atherosclerotic cardiovascular disease 13, 16, 52, 139, 618, 735, 762, 862, 902
use of 439
Atherosclerotic disease 247
Atherosclerotic renal artery 248
stenosis 247, 248, 248t, 325, 599
Atherosclerotic renovascular disease 295
Atherothrombosis, reduction of 946
Athlete's heart 444, 448
Atomoxetine 253
Atorvastatin 717
Atrial fibrillation 153, 163, 209, 261, 357, 365, 386, 430433, 453, 485f, 488, 631, 726, 752, 796, 797, 799
mechanisms of 430
pathophysiology of 431f
permanent 363
reduction of 726
risk of 431, 432
Atrial filling velocity 402
Atrial natriuretic peptide 25, 40, 121, 421, 526, 779, 947
Atrial septal defect 923
Atrioventricular junction changes 100
Atrophic thyroiditis 864
Augmentation index 93
Augmenting aortic diastolic pressure 289
Auscultatory gap 691
Automated blood pressure measurement technique 691
Automated implantable cardioverter defibrillator 233
Automated myocardium tracking 369
Autonomic cardiovascular control, attenuation of 90
Autonomic dysfunction 87, 276
Autonomic modulation 491
Autonomic nervous system 24
alterations, mechanisms of 88
dysfunction 86
role of 86
Auxiliary nurse midwife 3, 202
Avanafil 179
Axillary lymphadenopathy 146
AYUSH doctors, role of 5
Azilsartan 728, 824826, 826f
benefits of 825f
medoxomil 728
use of 825
Azole antifungals 719
B
Back pain 216
Bacteremia 216
Balloon
angioplasty 113, 149, 249
dilatation 148
Banana peel appearance 589f
Baroreceptor 121
Baroreceptor activation therapy 160, 635, 636, 943, 944
role of 636
Baroreceptor failure syndrome 900
Baroreceptor reflex 898, 901f
hyperactivity 821
Baroreflex activation therapy implants system, location of 637f
Baroreflex failure 899
Basal ganglia, bilateral 553f
Basal sympathetic tone 73
Behçet's arteritis 216
Behçet's disease 563
Benazapril 789
Bendroflumethiazide 409, 742, 763
Benzothiadiazine 409
backbone 763
chemical structure of 409f
Bergamo Nephrologic Diabetes Complication Trial 41
Berlin questionnaire 30
Beta-adrenergic blockade 480, 817, 942
Beta-blockers 74, 148, 161, 171, 191t, 244, 341, 375, 500, 606, 619, 696, 735, 736t, 743, 744, 789, 790, 821, 845, 874
antihypertensive effects of 697fc
benefits of 699
classification of 696
generations of 697t
use of 699
vasodilating 861
Betaxolol 697
Bicaval dual-lumen cannula 917
Bicuspid aortic valve 216, 568, 569f
Bile acid-binding resin 718
Biochemical derangements, new-onset of 872
Biological neural network 330
analogy of 330f
Biopsy, endomyocardial 541
Biplane Simpson's method 461
Bisoprolol 75, 277, 697, 703, 704, 704t, 712714
effects of 712
Black blood 320
Black carbon 95
Bleedings, minor 610
Blood
arterial inflow 73
brain barrier 100, 550, 839, 841
cholesterol 376
glucose control 956
oxygen 314, 596, 599
level-dependent 316f
pressure 3, 7, 1113, 25, 56, 78, 94, 97f, 103, 112, 127, 134, 188, 193, 214, 220, 251, 260, 265, 276, 306, 321f, 343, 355, 395, 414, 420, 430, 457, 474, 495, 498, 507, 517, 522, 533, 567, 605, 612, 613, 616, 622, 630, 640, 670f, 679, 691, 692t, 694, 711, 754t, 762, 788f, 802b, 803, 818, 820, 885, 887b, 908, 932, 955
arterial 694
brachial 288, 290, 292
categories of 440t
central 253
circadian rhythm of 279
classification of 7, 11t, 343t
components of 24f
control of 188, 343, 735, 805, 906
diastolic 9f, 12, 30, 45, 50, 57, 79f, 80, 115, 160f, 184, 190, 196, 259, 272, 298, 371, 424f, 440, 507, 605, 612, 645f, 670f, 680, 692, 698, 711, 741, 754, 771, 780, 801, 817f, 832, 849, 914, 932, 936, 942, 949f
elevated 443, 731, 808, 831, 849
exercise induced 706, 712
goal 115, 210, 471, 625, 753
guidelines of 57t
high 15, 45, 158, 257, 313f, 331, 343t, 358, 644, 692, 743, 869
intensive 275, 432
intraprocedural management of 617
levels, classification of 689t
lowering of 671, 740f, 779
management of 45, 47, 290, 440, 551, 605, 847fc
measurement 257, 258, 259f, 260t, 267t, 294, 689693, 869, 907, 951
mechanisms of 156
mildly elevated 933
monitoring 157
nervous control of 898
office measurement of 344t
pediatric 831t
perioperative control of 190
postprocedural management of 617
postural variability of 820
preoperative management of 616
profile, normal ambulatory 268f
reduction in 79f, 397, 436, 711, 712, 739, 793, 839
rhythm of 695
rise in 426
salt sensitivity of 119
self-measurement of 265f
status, classification of 952
target 46, 117, 159, 682, 816, 817t, 953
variability 183185, 694
tissue interface 444
urea nitrogen 907
vessels 775
volume 23, 26, 139
Body
mass index 17, 34, 54, 129, 211, 499, 698, 798, 857, 872, 879
sodium, abnormal 25
surface area 353, 444, 833
Bonnet's sign 100
Booster pump
functions 362
phase 362
Bowman's capsule 414
Bradykinin 550
Brahmakumaris Rajyoga Meditative 67
Brain 280, 721, 775
hemorrhage 879
magnetic resonance imaging of 321f
natriuretic peptide 25, 421, 487, 526
Branch retinal vein occlusions 104f
Breath, shortness of 792
Breathing disorders 481
British Hypertension Society 189, 690, 698
Broken heart syndrome 388
Bronchitis 95
Bruit over subclavian arteries 146
B-type natriuretic peptide 479, 942
Buckberg index 394
Bull's eye plot 449f
Bumetanide 739, 742
C
Caffeine 254
Calcific aortic valve disease 405
Calcific stenosis, incidence of 426
Calcineurin inhibitor 662, 663
Calcium 475f, 543f
activated potassium 740
antagonists 380, 543, 723
channel antagonist 51, 160f
channel blockers 41, 54, 75, 148, 161, 179, 186, 210, 284, 421, 474, 500, 606, 617619, 647, 664, 670, 696, 699, 733, 735, 741, 744, 748, 763, 788, 790, 818, 824, 857, 874, 905, 908, 936, 946, 952
long-acting 154, 834
homeostasis 746
abnormal 485
intracellular concentration of 859
ions, active transport of 453
phosphorus product 844
supplementation 871
Caloric intake 17
Calorie restriction 41
Canadian Hypertension Education Program 46, 358
Canagliflozin 621, 783, 785
Cancer 95
Candesartan 726
Capillary rarefaction 443
Captopril 167, 192
prevention project 744
renal scintigraphy 576
Carbon dioxide 914
Carbonic anhydrase 740
inhibitors 746
Carcinoid syndrome 897
Cardiac biomarkers, rise of 388
Cardiac catheterization 248t, 489
Cardiac chamber hypertrophy 337
Cardiac damage 793
Cardiac failure 397, 906fc
Cardiac function 475b
heart failure, treatment of preserved 942
Cardiac intensive care management 918
Cardiac magnetic resonance 320f
imaging 358, 489, 541
Cardiac output 23, 26
Cardiac pacemaker-mediated hypertension treatment 943
Cardiac phase and flow dependent techniques 597
Cardiac risk index, revised 191
Cardiac systolic function 463
Cardiac tamponade 216
Cardiac transplant 233
Cardiological Society of India 133
Cardiomyocyte
hypertrophy 417
titin hypophosphorylation 485
Cardiomyopathy 485f
hypertensive 537
hypertrophic 372, 443, 444, 447f, 449f
obstructive 714
Cardioprotective drugs 341
Cardiopulmonary bypass 188, 190
Cardiorenal syndrome 486, 494, 501
clinical presentations of 495
development of 496fc
pathophysiology of 495
Cardioselective beta-blockers 703
Cardioselective beta-blockers, advantages of 699
Cardiovascular accident 63, 68
Cardiovascular changes, assessment of 419
Cardiovascular death 609
Cardiovascular diseases 15, 38, 45, 79, 107, 115, 133, 157, 160f, 173, 183, 196, 209, 222, 257, 281, 294, 299, 301, 353, 396, 494, 510, 526, 696, 722, 733, 752, 760, 775, 811, 815, 844, 846t, 860, 879, 931, 950
comorbidities 716
development of 94
metabolism in 527
risk factors for 331, 726, 947
Cardiovascular events, risk of 354
Cardiovascular magnetic resonance 233, 575578
Cardiovascular mortality 417, 519
Cardiovascular protection 726
Cardiovascular risk 110, 117, 185, 845
factors 718
predictor of 292
Cardiovascular sequelae, long-term 222
Cardiovascular system 224f, 614, 891
Carney's triad 309
Carotid arterial wall stiffness 845
Carotid artery 899
common 141f
disease 669
asymptomatic 671
internal 898
stenosis 671
Carotid baroreceptor activation therapy 804
Carotid chemoreceptors 898
Carotid disease 670
Carotid duplex ultrasound 296
Carotid intima media thickness 141, 141f, 147, 290, 416, 845
Carotid sinus 898
Carotid stenosis 672
bilateral severe 671
degrees of 670
Carteolol 697
Carvedilol 75, 697, 737
Catecholamines 307, 391
Catheter-based renal artery denervation 635
role of 635
Cavernosal artery 376, 377, 377f
Cavernosal muscles 376
Cavernosal sinusoids 375f
Celiprolol 697
Celoria-Patton classification 569
Centers for Disease Control and Prevention 298, 618
Central aortic augmentation index, estimation of 292f
Central aortic blood pressure monitoring, significance of 288
Central aortic pressure 150, 288, 289, 289f, 290, 291f, 708, 712
determinants of 289f
measurement of 289
role of 290
Central aortic pulse pressure 947
Central aortic systolic pressure 289, 290, 291f, 947
Central nervous system 320, 457, 842
Central pressure waveform 649f
Central renal sympathetic nervous systems 121f
Central retinal arterial occlusion 104f
Central retinal vein occlusion 103, 104f
Cerebral blood flow 550
autoregulation 549
Cerebral blood vessels 550f
Cerebral disturbances 873, 878
Cerebral hemorrhage, nontraumatic 841
Cerebral infarction 306, 792
Cerebral ischemia trial 671
Cerebral small vessel disease 552, 553
Cerebrolysin 556
Cerebrovascular abnormalities, development of 282
Cerebrovascular accident 389, 625, 872
hemorrhage 192
Cerebrovascular disease, childhood 840
Cerebrovascular diseases 167, 183, 196, 211, 257, 281, 282, 296, 679
unilateral 840
Charcot-Bouchard aneurysm 296
Chemotherapy
drugs 900t
understanding 897
Chennai Urban Rural Epidemiology Study 39
Chest
pain 216
X-ray 147, 224
Child-Pugh classification 518
Chlorothiazide 409
chemical structure of 409f
Chlorthalidone 148, 277, 409412, 414, 417, 419, 421, 543, 544, 619, 733, 739, 741743, 745, 746, 748, 762764, 826
effect of low-dose 764f
indications of 410
Cholesterol 711, 733
synthesis pathway 716
Chondroitin proteoglycans 556
Choroidal vessels 100
Choroidopathy, hypertensive 102
Chronic critical limb ischemia 679
Chronic kidney disease 23, 38, 47, 63, 116, 129, 149f, 156, 157fc, 190, 210, 265, 281, 295, 296, 314, 344, 398, 424, 494497, 498fc, 498t, 618, 638, 651, 660, 682, 739, 752, 801, 812f, 832, 844, 849 861, 897, 914, 944, 947, 955
related risk factors 497fc
Chronic kidney failure 280
Chronic obstructive
airway disease 209
lung disease 714
pulmonary disease 67, 95, 139, 241, 485f, 713
Chronotherapy 211
Cilnidipine 284
Circadian rhythm, pathophysiology of altered 280
Clarithromycin 719
Clevidipine 793, 794
Clonidine 192, 804
withdrawal 192
Cocaine
particularly 914
toxicity 793
use of 946
Cochlear implant 327
Coenzyme
A 716
Q10 885, 886
Cognitive function, protection of 728
Color Doppler
flow 586
ultrasound Kolkata score 147
Coma 216
Combination therapy
advantages of 788, 788f
rationale for 787
Common carotid
artery, left 569
lesion, left mid 145
Community Health Center 202
Comprehensive transthoracic echocardiography 559
Computed tomography 153, 225, 242, 585, 623
angiography 559, 567, 576, 850
scan 169
contrast-enhanced 242
Congenital renal structural anomalies 847
Congestive heart failure 25, 280, 295, 495, 508, 538, 713, 731, 745, 747, 798, 905, 951
causes of 845, 851
Conn's syndrome 23, 163, 166, 167, 307
Connective tissue growth factor 40
Constrictive pericarditis 383
Continuous noise 106
Continuous positive airway pressure 29, 283
Continuous venovenous ultrafiltration 501
Contraceptives 53
combined hormonal 53
Conventional auscultatory office blood pressure 294
Cornell criteria 302
modified 302
Coronary artery bypass
grafting 235, 622
robot-assisted 234f
surgery 623
minimally invasive direct 235
Coronary artery
arterial 235
calcification 845
disease 47, 56, 61, 63, 68, 78, 83, 116, 163, 209, 233, 331, 436, 344, 394, 469, 484, 485f, 537, 605, 614, 616, 618, 622, 634, 647, 679, 703, 731, 733fc, 744, 768, 794, 815, 817, 944, 951
involvement 145
risk development 49, 64, 134, 197
surgery, minimally invasive 235
Coronary atherosclerotic process 699
Coronary flow reserve 391
Coronary heart disease 116, 173, 299, 394, 396f, 439, 614, 698, 717, 762, 930
high risk of 700
Coronary perfusion 816
Coronavirus disease 2019 83, 265
Corpora cavernosa 376
Corpus spongiosum 377f
Corticosteroids 147
Corticosterone 850
Corticotropin-releasing hormone 63, 68, 308
Cortisol 850
COVID-19 83, 84
Cranial nerve palsies 103
C-reactive protein 33, 97f, 141, 146, 298, 299, 683
C-type natriuretic peptide 25, 526
Cube formula 338
Cuff-pressure 694
exceeding systolic pressure 694
Cushing's disease 23
Cushing's reaction 899
Cushing's syndrome 16, 134, 295, 308
clinical diagnosis of 308
Cyanosis 878
Cyclic adenosine monophosphate 120, 696
Cyclic guanosine monophosphate 138, 176, 179, 193, 485f, 486f, 519, 887
Cyclooxygenase pathway 891
Cyclosporine 719, 802, 906
Cytochrome p450 697, 775
D
Dabigatran 796798
Dahl salt-sensitive
animals 887
rats 885
Dapagliflozin 621, 783, 785
Debakey classification 215, 240
Dementia 781
Deoxycorticosterone 850
Depression 395
role of 64
Device-based hypertension management strategies 942
Dexamethasone suppression test 170
Dexmethylphenidate 906
Dextroamphetamine 906
Diabetes 38, 47, 101, 116, 139, 210, 275, 344, 357, 374, 376, 469, 539, 618, 717, 722, 785
control and complications trial 39
mellitus 15, 38, 101, 103, 129, 198, 433, 508, 539, 611, 620, 624, 646, 679, 727, 752, 812f, 832, 851, 873, 897, 931, 930, 947
insulin resistance 20
prevention of 727
prevalence of 201f
progression of 719
treatment of 201f
type 1 51
type 2 51, 821
Diaphragm 560f
Diarrhea 781
Diastolic blood pressure 9f, 12, 30, 45, 50, 57, 79f, 80, 115, 160f, 184, 190, 196, 259, 272, 298, 371, 424f, 440, 507, 605, 612, 645f, 670f, 680, 692, 698, 711, 741, 754, 771, 780, 801, 817f, 832, 849, 914, 932, 936, 942, 949f
Diastolic dysfunction 301, 318, 369, 386, 389, 391, 415, 446, 452, 457, 846
degrees of 446
early identification of 363
effect of 430
evaluation of 363
mild 415f
normal 415f
parameters of 418
severe 415f
valsartan in 479
Diastolic function 463
grades of 489t
group 338, 371
Dietary approaches to stop hypertension 17, 18, 59, 123, 160, 197, 199, 803, 811, 834
Dietary modifications 41
Dietary salt restriction 803, 907
Diethylenetriamine penta-acetic acid 159
Different blood pressure measuring devices 693
Diffuse interstitial fibrosis 368
Diffuse mid-thoracic long-segment obstruction 836
Diffusion tensor imaging 598
Diffusion-weighted imaging 555f, 599
Digital devices, use of 5
Digital pulse amplitude tonometry 141
Dihydropyridine 42, 161, 619, 698
calcium channel blockers 171, 632, 793
Dimethylacetamide 409
Dimethylformamide 409
Dimethylsulfoxide 409
Diminished femoral pulses 907
Dipeptidyl peptidase-4 inhibitors 621
Dipyridamole 147
Direct renin inhibitor 664, 769, 770, 789
Disability-adjusted life years 196
DISHA study 204
Disseminated intravascular coagulation 879
Distal arch hypoplasia 569f
Distal brachiocephalic trunk, lesions of 145
Diuretics 148, 160, 419, 422, 480, 499, 607, 744, 752, 789, 804, 818, 821, 874
action of 741
adverse effects for 747t
effect 414, 746t, 784
four sites of action of 741f
mechanism of action of 414f
pharmacodynamics of 742t
pharmacokinetics of 742t
role of 421
therapy 735
echocardiography targets for 415
inadequate 946
low-dose 748
use 414
long-term 416
Domperidone 253, 822
Doppler
flow profile 377t
gradients 428
parameters 588
Double jeopardy echo evaluation 426
Doxazosin 277, 822
Drospirenone 54
Droxidopa 253
Drug
allergy 747
interactions 717, 722
intoxication 872
resistant 948
therapy 804
monitoring 272
treatment 123
Dual antiplatelet therapy 555
Dual calcium channel blockers 789
Dual chamber pacemakers 365
Duplex ultrasound 248, 326, 576
Dysautonomia 820
Dyslipidemia 16, 19, 20, 275, 374, 716, 717, 719, 897
atherogenic 858
management 41
E
Early diastolic annular velocity 369
Early morning blood pressure surge 185
Echocardiogram 134
Echocardiographic diastolic dysfunction 386
Echocardiography 351, 355f, 357, 358, 368, 414, 415, 487, 541
advance 537
conventional 368
monitoring 414
role of 398, 457
Eclampsia 192, 692, 793, 795, 878, 880
Ectopic glands 312
Edema 411
Edinburgh claudication questionnaire 681
Edoxaban 797, 798
Ehlers-Danlos syndrome 216
Eighth Joint National Committee 748
Ejection fraction 469, 487, 509f, 833, 949
low 630
reduced 446, 772
Elastic artery, large 145
Elastic lamina layers 318
Electrocardiogram 134, 225, 457, 577, 871
left ventricular hypertrophy 302f, 303f
Electrocardiography 153, 443, 541
Electronic devices 694
Electronic health record 331
Electronic medical records 329
Electronic pressure sensor 694
Elevated plasma metanephrine concentrations 311
Elschnig spots 102
Embolic disease 325
Emerging therapies, role of 423
Empagliflozin 621, 784
Enalapril 529, 724
Enalaprilat 794
Encephalitis 872
Encephalopathy, hypertensive 3, 192, 792, 841, 872
End-diastolic antegrade velocity 378
End-diastolic velocity 379, 590, 590f
End-diastolic volume 372
Endoleaks, classification of 226f
Endoplasmic reticulum 906
End-organ damage 129, 875
presence of 847
Endothelial cells, regulation by 550
Endothelial dysfunction 25, 72f, 120, 138, 139fc, 141f, 142, 375, 378f, 379, 858, 865, 885, 891, 905
correction of 141
reduction in 784
role of 93
Endothelial function 142
assessment of 140, 141
Endothelial nitric oxide 664
synthase 718f, 906
Endothelial progenitor cells 93
Endothelial tight junctions 841
Endothelin 25, 97f, 859
antagonism 500
receptor
antagonist 423, 643
blocker 423
system 120
Endothelium 139
derived nitric oxide 885
role of 138
Endovascular baroreflex amplification 943
Endovascular techniques 148
Endovascular therapy 225, 231
Endovascular treatment, role of 219
Endpoint reduction, losartan intervention for 744
Epicardial coronary artery 391
Epilepsy 872
Epinephrine 307, 696
Epistaxis, shortness of 792
Eplerenone 422, 423, 739, 741, 742, 747, 771, 775, 776, 777f
structure of 776f
Epoxyeicosatrienoic acids 121
Epworth sleepiness scale 30
Erectile dysfunction 7275, 110, 111, 111f, 112, 178, 180f, 374, 376t, 378f, 380, 395, 727, 771
basic management of 112
causes of 374, 375f
diagnosis of 376
evaluation of 376
management of 76fc, 380
mechanism of 179
mediator of 74
pathophysiology of 374
report of 75f
syndrome, physiology of 380
Erectile functions, antihypertensive on 380t
Erection hardness score 379
Erythrocyte sedimentation rate 146
unexplained high 145
Erythromycin 719, 776
Erythropoietin 253, 802, 822, 906
stimulating agents 16
Esaxerenone 772
Esmolol 193, 218, 438, 697, 794
Essential hypertension 73, 131, 704, 711, 776, 822
male pathophysiology in 73
Estimated glomerular filtration rate 116, 157, 295, 296, 410, 494, 519, 946, 955
European Association of Cardiovascular Imaging 337, 360, 446
European Diabetes Prospective Complication Group Study 39
European Lacidipine Study on Atherosclerosis 744
European Society of Anesthesiology 190, 191
European Society of Cardiology 8, 46, 5052, 56, 57, 115, 116, 127, 134, 158, 190, 191, 210, 220, 273, 337, 398, 420, 473, 474f, 487, 524, 526, 535, 537, 574, 754, 944, 951
Guidelines 268, 543
European Society of Hypertension 11, 46, 56, 57, 115, 116, 127, 398, 420, 535, 537, 543, 574, 754, 944, 952
Excess sodium intake 18, 198
Exercise 18, 78, 80t, 692, 803, 936
stress echocardiography 389
training 490, 936
Extracellular fluid 518
volume 424
Extracellular matrix 486f
fibrillar collagen 453
Extracellular volume 369
Extracorporeal cardiopulmonary resuscitation 916
Extracorporeal life support 914, 923
applications 917f
devices 914f
modes of 923t
Extracorporeal membrane oxygenation 911, 913, 914, 916918, 919f, 920, 920t, 923
circuit 920b
peripheral venoarterial 923f
venovenous 922f
contraindications of 921
properties 920
role of 916
therapy 918
types of 918
uses of 914
venoarterial 917
Extrinsic compression 585
Extrinsic fibrous band 585
Exudative retinal detachment 102
Eye 99, 344
changes, classification of 146fc
Ezetimibe 717
F
Fabry's disease 444
Familial pheochromocytoma-paraganglioma syndrome 309
Familial primary aldosteronism 170
type 1 164
type 2 164
Familial thoracic aortic aneurysm and dissection syndrome 216
Fasting glucose, impaired 16
Fat
content 17
poor adenoma 308
Fatigue 146
Fatty liver disease, nonalcoholic 648f, 651
Felodipine event reduction 743
Femoral vascular access, absence of 917
Femoral vein, right 922f
Fenoldopam 218, 243, 794
Fever 146, 743
Fiber diet, low 946
Fibroblast growth factor 452
Fibromuscular disease 585
Fibromuscular dysplasia 247, 248, 295, 585, 591, 592, 592f, 596, 600, 840, 850
Fibromuscular hyperplasia 16
Fibrosis 417
interstitial 443
Finerenone 772
First-tier screening tests 166
Fistulas 376
Flow-mediated dilation 140, 140f
Fludrocortisone 253
Fluids
and salt 252
overload 411
Fluvastatin 717
Focal arteriolar attenuation 102f
Food and Drug Administration 526, 620, 722
Food interactions 722
Food Safety and Standards Authority of India 203
Fournier's gangrene 785
Fourth National Family Health Survey 440
Fractional anisotropy 598
Fractures 376
Framingham Heart Study 7, 197, 538, 575
Frank systolic dysfunction 448
Free fatty acid 858, 859
Friedreich's ataxia 444
Furosemide 739, 742
stimulation test 168
G
G protein-coupled receptor 174
Gamma-glutamyl transferase 50
Gestational hypertension 53, 54, 870, 872t, 873, 878, 879
management of 872
mild cases of 879
severe cases of 880
Giant cell arteritis 216
Glasgow Coma Scale, low 507
Glaucoma 103
Gliflozins 784
Global burden of disease 3, 115, 196, 398
study 178
Global circumferential strain 384, 385
Global longitudinal strain 338, 340, 353, 369, 371, 384, 386f, 542
polar map of 354f
Global radial strain 384, 385
Glomerular filtration rate 59, 421, 496, 526, 596, 598, 599, 651, 648f, 740, 747, 941
Glomerulonephritis, chronic 325
Glucagon-like peptide 503, 620
Glucocorticoids 165f, 171, 850
inducible kinase 1 165f
mediated effects 663
receptor activation pathway 120
Glucose
dependent insulinotropic polypeptide 620
imbalance, acute 610
metabolism, abnormal 163
Glutathione 721f, 932
Glycemic control 41
Graves’ disease 867
Great Indian blood pressure survey 133
Guanfacine 421
Guanosine monophosphate 779
Guideline directed medical therapy 635, 640
Gynecomastia 771
H
Happy mind, lifestyle for 67
Hashimoto's disease 864
Hatha yoga 929
Head injury 872
Headache 146, 736, 792
Head-up tilt test 653
Health disease continuum 652f
Healthcare professionals 4
Healthy body, lifestyle for 67
Healthy heart, lifestyle for 67
Heart 280, 622, 775
attack 95, 222
acute 613
diastolic
dysfunction of 848
function of 399
disease 785
congenital 53, 832, 847
extracardiac 316
hypertensive 295, 301, 345, 351, 358, 368, 370t, 383, 385f, 386, 399, 448, 455f, 457, 469, 470, 484, 533, 537, 544
ischemic 10f, 191, 209, 210, 262, 398, 879
sign of hypertensive 403
failure 78, 83, 88, 163, 209, 216, 234f, 281, 282, 338, 354, 357, 427, 432, 443, 469, 474f476f, 478, 485f, 487t, 494, 507, 510f, 513, 522, 533535, 539f, 543f, 574, 618, 623, 632, 646, 699, 727, 763, 779, 844, 845, 846t
chronic 474f, 495, 502, 519
decompensated 502
development of 383, 517
diastolic 359, 942
effective therapy for 490
guidelines, recent updates of 519
hypertensive acute 640
left ventricular hypertrophy to 540
long-standing hypertension leading to 232
morbidity in 529
pathological changes in 479
pathophysiology of 479
phenotypes of 330
prevalence of 537
resistance hypertension with 956
risk factor for 301, 414, 458, 787
signs of 488t
stage of 471, 472
symptoms of 453, 488t
systolic 359, 415
therapy, goals of 518
treatment of hypertension in 473
uncontrolled hypertension to 478
with midrange ejection fraction 487
with normal ejection fraction 905
with preserved ejection fraction 152, 365, 462, 476, 481, 484, 485, 486f, 529, 540, 941
with reduced ejection fraction 152, 476, 484, 485, 528, 539, 539f, 736, 905, 953
hyperkinetic 649
outcomes prevention evaluation 39, 154, 284, 472, 759
study 614
rate 63, 68, 79, 97f, 454, 475, 647, 703, 711, 795
reserve 80
syndromes, hypertrophic 444
systolic function of 399
transplant 495
recipients, care of 664
Heart Failure Society of America 526, 527
HELLP syndrome 878, 880
Hematoma 376
acute intramural 572
intramural 230, 318, 559, 563, 572, 577
Hemiretinal vein occlusion 103
Hemoglobin, glycated 364
Hemorrhage
intracerebral 320, 549, 551, 840
intraventricular 840
subarachnoid 306, 320, 389, 549, 795, 840
subconjunctival 103
Hemorrhagic complications 434
Hepatocellular carcinoma 308, 897
Herbal supplements 946
High blood pressure 15, 45, 158, 257, 343t, 358, 644, 743, 869
High peak systolic velocity 591f
High-risk percutaneous coronary intervention 918
High-sodium diet 835
High-systolic velocity 590f
Histocompatibility complex, major 718f
Hlomerulonephritis 314
Home blood pressure
measurement 12, 693
monitoring 12, 184, 257260, 262, 294, 343, 654, 694, 768, 936, 951
Hormonal replacement therapy 53, 54
Household air pollution 95
Human brain 330, 331
Human genes and salt sensitivity 122
Human immunodeficiency virus infection 717
Hybrid myocardial revascularization 235
Hydralazine 193, 794, 804, 874
hydrochloride 742
Hydrochlorothiazide 148, 409, 412, 414, 421, 499, 531, 619, 724, 739, 742, 743, 746, 748, 763, 764
Hyperaldosteronism 23, 166, 309f
bilateral 163
primary 134, 166, 167fc, 168fc, 307, 312
secondary 741
tertiary 164
Hyperbaric index 869
Hypercalcemia 16, 410, 754
Hypercalciuria, idiopathic 746
Hypercholesterolemia 648, 717
Hypercholesterolemia, familial 344
Hypercoagulable state 585, 858
Hypercortisolism 310f
Hyperemia, induction of 391
Hyperglycemia 507, 746, 859
Hyperinsulinemia 121, 858
Hyperkalemia 23, 745, 771, 777, 811
risk of 818
Hyperkyphosis 260
Hyperlipidemia 747, 858
Hyperparathyroidism, primary 16
Hyperplasia, benign prostatic 181
Hypertension 3, 1113, 19, 2328, 30b, 38, 46, 51, 56, 58, 72, 78, 79f, 80t, 8688, 9496, 99, 103, 110, 111f, 119, 129f, 131, 135b, 136, 139fc, 141f, 146fc, 149, 156, 163, 166, 178, 180f, 181, 186, 201, 201f, 202f, 209211, 222, 240, 244, 257, 271f, 275, 281, 296299, 301, 321f, 331, 344, 353, 362, 368, 372, 374, 380, 386f, 398, 404, 414f, 426428, 431f, 432434, 439, 448, 469, 471, 474b, 476, 490, 507509, 510f, 517, 523, 530, 537540, 547, 553, 559, 570, 583, 603, 609611, 616, 622, 627, 634, 643, 662, 669, 677, 696, 703, 704, 704t, 714, 717, 726728, 731, 733fc, 739, 748, 757, 764f, 766, 779, 785, 795, 799, 815, 824, 829, 836f, 849, 852fc, 857, 861, 867, 869, 878, 885b, 890, 891fc, 899, 911, 914, 930, 941, 952
accelerated 872, 914
acute severe 736
antecedent 609
aortic
causes of 568
complications of 568, 571
computed tomography evaluation of 567
arterial chronic 609
assessing control of 270
associated brain hemorrhage, incidence of 841
associated bruits 166
awareness 200
baseline investigations for 295b
category of 824
causes of 568, 625b, 815
central 948
childhood 832
chronic 54, 317, 383, 744, 844, 870, 878, 879
effects of 841
chronotherapy of 284
classification of 7, 9, 10, 189t, 870
clinical management of 3
combination therapy of 744
complications of 317, 318t
components of 23
control of 41, 343, 432, 737, 872
cut-offs for 439
development of 859fc
diagnosis 57, 115, 115t, 134, 267t, 269, 270f, 832, 839
methodology in 255
diastolic 88
diuretics in 414, 739
drug combinations in 790t
duration of 73
early stages of 361
early-onset 133
effect of 550f, 839, 878
epidemiology of 696
essential 73, 131, 704, 711, 776, 822
etiopathogenesis of 146
evaluation of 101, 267, 457fc, 458, 568b, 850
familial 23
family history of 850
genetic basis of 24
gestational 53, 54, 870, 872t, 873, 878, 879
global burden of 38
grading of 870
guidelines 698
history of 401
inappropriate 295
incidental detection of 453
insulin resistance induced 610
investigation for 134
isolated systolic 45, 47, 57, 88, 93, 134, 275, 644, 645f, 649, 743
longstanding 394
long-term 704, 711
management 20, 69fc, 101, 134, 135b, 148, 188, 279, 437, 439, 472, 498fc, 605, 625, 631, 640642, 671, 726, 766, 846, 847, 849, 851, 879, 900, 941
strategies for 831
telmisartan in 721
masked 159, 260, 262, 263, 270, 295, 654, 691, 849
measurement 262
mechanism of 31, 865, 897, 898f
mediated end-organ damage 61, 63, 68
Mendelian forms of 24
mild 870
mild-to-moderate 362, 712, 833, 947
mitigate menace of 757
moderate 870
nonendocrine causes of secondary 314
onset of early 133
optimal treatment of 471
organ damage 295, 297
overtreatment of 394
paroxysmal 914
pathogenesis of secondary 568
pathophysiological determinants of 15, 196
pathophysiology of 23, 23fc, 28, 28fc, 157fc, 858, 864, 885, 906fc
perioperative 793
surgical implications of 624
pharmacological
management of 31
therapy of 873
phenotype 159t
poorly controlled 355
positive family history of 835
post-transplantation 662
pregnancy-related 107
presence of 428t
prevalence of 700, 801, 840, 849, 850
prevention 946
and control initiatives in India 201
preventive strategies and campaign in India 196
primary 23, 808, 850
prevention of 199
radiation-induced 897
receiving bisoprolol 711
reducing atrial fibrillation 433
refractory 420, 769
risk factors for 15, 50, 61
secondary 51, 134, 134b, 163, 306, 312f, 325, 808, 835, 850
cause of 294, 295t, 576, 812
setting of 267
severe 163, 166, 507, 817, 870, 875t
severity of 73, 73f, 88, 847
small resistance arteries 92
Society of India 202
stage 1 92, 167, 362
stage 2 51, 92, 167, 362, 748
stress leading to 930fc
study, treatment of mild 765
substrates of 23, 24f, 26
supine 644, 650
symptomatic 51
systolic 88, 393, 472, 644, 651, 743, 744, 752
terminology used in 898t
therapeutic targets of 24f, 26
to heart failure 469, 949fc
treatment of 23, 199t, 200, 616, 641, 726, 728, 733, 834, 835, 886, 946
true resistant 88, 420
uncomplicated 158f
uncontrolled 222, 607, 817
urgent control of severe 875
use in
essential 736
pediatric 737
vessel remodeling in 25
with heart failure 512, 955
Hypertensive 129f, 680
action, mechanism of 718fc
acute aortic syndrome 577
crisis 243, 462, 792
diagnosis of 792
echocardiographic evaluation of 458
occurrence of 792
parenteral drug therapy for 193t
perioperative management of 192
presentation of 792
disorders 878, 880
complications of 870, 871b
management of 869, 872
nomenclature of 878
pathophysiology of 870
emergencies 3, 243, 457, 793, 817, 914, 915b
treatment of 793, 794t
episodes 192
heart disease 295, 301, 345, 351, 358, 368, 370t, 383, 386, 399, 448, 455f, 457, 469, 470, 484, 533, 537, 544
classification of 485t
development of 453
pathophysiology of 452, 470, 484
staging of 233f, 538f
retinopathy 99101
classification of 100t, 101t
evaluation of 101
signs of 102f
small-artery disease 554
target-organ damage 51
urgency 3, 243
treatment of 793
Hyperthyroid 867
Hyperthyroidism 16, 313, 867
experimental model of 867
management of 867
Hypertrophy
asymmetrical 448f
benign prostatic 395
cardiac 446, 717
hypertensive 453
hypertensive left ventricular 384f
moderate 444
severe 444
Hyperuricemia 410, 727, 746, 754
Hypoalbuminemic states 421
Hypochondrial pain, right 873
Hypoechoic nodular lesions 313f
Hypoglycemia 507
Hypokalemia 166, 167, 410, 745, 748, 789
Hypomagnesemia 410, 745
Hyponatremia 410, 745, 748, 754
Hypopneas 33
Hypotension
diastolic 393, 395, 865
severe 507
Hypotensive drugs, multiple low-dose 759t
Hypothalamic-pituitary-adrenal axis, activation of 929
Hypothyroid 864
Hypothyroidism 16, 134, 313, 314f, 864867
causes of 313
congenital 313
primary 864
I
Idiopathic chronic inflammatory disease 145
Immune system 122
Implantable cardioverter-defibrillator 630
Impotence 736, 747
Impulsive noise 106
Indapamide 409, 412, 414, 417, 543, 544, 619, 739, 742, 748, 763, 765
Infarction 216
Infections 872
Inferior vena cava 416, 417f, 458, 586, 920
Inflammation 497
role of 139
Inflammatory disorder 298
Inflammatory vasculitides 216
Infradiaphragmatic lesions 150
Inotropes 502
Insulin
induced endothelium-dependent vasodilation 859
resistance 610, 727, 858, 859
homeostasis model assessment of 346
role of 858
sensitivity 700
Intensity projections, minimum 567
Intensive care unit 216
Interatrial shunt device 491
Intercellular adhesion molecule 1 141
Interleukins 892
Intermittent claudication 681
Intermittent noise 106
International Diabetes Federation 46
International Index of Erectile Function 112
International Registry of Acute Aortic Dissection 242
International Society of Heart and Lung Transplantation 662
International Society of Hypertension 8, 10, 11, 46, 158, 474b, 760
International Verapamil-Trandolapril Study 645, 744
Interventricular septal thickness 296
Interventricular septum 352f
Intimal dissection 247
Intimal injury, point of 214f
Intra-aortic balloon
counterpulsation 612
pump 502, 913, 915
Intracellular calcium homeostasis 891
Intracellular proteins, large number of 864
Intracranial pressure 794, 795
Intractable ventricular arrhythmias, severe 438
Intraocular pressure 100
Intraoperative blood pressure reduction strategies 192
Intrarenal disease 835
Intrauterine death 873
Intrauterine growth
restriction 651
retardation 648f, 872
Iodine deficiency 313
Iodothyronine deiodinase 867
Ion transport, impaired 121
Irbesartan 948
Ischemia 438
acute limb 679
apical subendocardial 389
Ischemic complications 434
Ischemic electrocardiogram, typical 388
Ischemic heart disease 10f, 191, 209, 210, 262, 398, 879
risk of 815
Ischemic stroke 549551, 840
rates of 840
Ishikawa criteria 145
Isometric resistance exercise 79
Ivabradine 480
J
Japanese Circulation Society 220
Jeopardizes heart 721
Joint National Committee 4, 9, 11, 12, 15, 46, 50, 544, 618, 627
seventh report of 158
Jugular vein, internal 920, 922f
Juxtaductal coarctation 569f
Juxtaglomerular apparatus 24
K
Kallikrein-Kinin system 121
Kaplan-Meier curves for cardiovascular mortality 129f
Kawasaki disease 585, 592
Ketoacidosis, euglycemic diabetic 621
Ketoconazole 776
Kidney 280, 775
abnormalities 847
damage, chronic 344
disease 38, 47, 158t, 357, 721, 861
end-stage 25, 885
history of 850
function
normal 424
tests 134
injury, acute 160, 497, 742
internal vasculature of 586f
transplant recipient 495
Korean Society of Heart Failure 520
Korotkoff sounds 690, 691
L
Labetalol 148, 193, 218, 697, 735, 737, 794
Lacunar infarct 555f
Lacunar strokes 553
Large artery 280
remodeling of 93
stiffening 648
L-arginine 886
Late diastolic annular velocity 369
Late gadolinium enhancement 369, 541
Leaflet sclerosis 427
Left atrial
cannula 917f
diameter 371
enlargement 403, 457
function 460
reservoir strain 338
stiffness 359
index 359
strain 362, 370, 383, 385
volume 338, 461
index 358, 371, 403
Left atrium 154f, 917
dilatation 418
size 416
strain of 345
Left bundle branch block 457
Left ventricle 920
measurements 353
strain of 344
Left ventricular
assist device 233, 913
diastolic
diameter 296
dysfunction 346, 361, 362, 364, 364f
function 370, 402, 459
dysfunction 296, 372, 741
ejection fraction 296, 338, 339, 347, 364, 368, 372, 426, 458, 478, 514, 523, 528, 529, 534, 614, 619, 663, 941
end-diastolic
diameter 371, 663
pressure 153, 303, 364, 539f, 920
pressure-to-volume ratio 663
volume 446
failure 794, 835
function 393
assessment of 388
geometry 351, 399, 401, 540, 411
remodeling 663
torsional deformation 340
Left ventricular hypertrophy 25, 55, 128, 152, 153, 154f, 155, 289, 295, 296, 301, 318, 320f, 337, 351, 358, 394, 398, 401, 410, 411, 427f, 436, 446, 452, 457, 469, 476f, 485, 495, 509, 533, 537, 540, 610, 630, 651, 744, 833, 844, 851, 858, 941
and vascular stiffness, regression of 707, 712
assessment of 368
development of 301, 383
diagnosis of 153, 301
different patterns of 411f
evaluation of 850
incidence of 414
pathophysiology of 452
regression and drugs 154
regression of 410
Left ventricular mass 352f, 353, 353t, 369, 458
and geometry 458
index 400t
measurement of 351, 353
Left ventricular myocardial
longitudinal strain 453
strain 372
Left ventricular strain 369, 372, 383, 386
systolic 371t
Left ventricular systolic function 370, 401, 417f, 458
echocardiographic assessment of 345f
Levitra 179
Liddle's syndrome 23, 24
Life after sprint 116
Lifestyle changes 159
Lifestyle interventions 907
Lifestyle modification 421
recommendations 952
Lifestyle-related chronic conditions 931
Ligamentum arteriosum 315
Linagliptin 503
Linear echocardiographic method 352f
Lipophilicity 717
Lipoprotein
high low-density 38
high-density 295, 711, 857
Lisinopril 723, 743
Listen Korotkoff sounds 690
Liver function
abnormal 508
impaired 878
tests 871, 872
Living kidney donor 495
Lixisenatide 503
Loeys-Dietz syndrome 216
Loop diuretics 499, 746, 846
Loop of Henle 414
Losartan 726
plus hydrochlorothiazide 723
suppression tests 167
Lovastatin 717, 719
extended-release 717
Low density lipoproteins 295, 857
Low diastolic blood pressure 393, 396f
and cardiac events 394
causes of 394
management strategies for 395
symptoms of 394
treatment of 395
Low plasma
antidiuretic hormone 410
protein-binding 703
renin 23
Low-density lipoprotein 299, 621, 683, 711, 762
cholesterol 718
receptors 716
Lower extremity arterial disease 296, 679
Lower limb ischemia 216
Lower respiratory tract infection 83
Low-frequency noise 106
Lumbar approach 586
Lupus anticoagulant 585
M
Macaroni's sign 147, 147f
Machine learning algorithms 329
Macroalbuminuria 39
Magnetic resonance angiogram 158, 899
contrast-enhanced three-dimensional 597
Magnetic resonance angiography 319f, 559, 576, 585, 598f, 599f, 850
contrast-enhanced 147
coronal reconstruction 595f
dynamic contrast 317f
Magnetic resonance imaging 153, 169, 242, 312f, 314f316f, 319f, 569
and aortography 242
aortogram 320f
evaluation 595
neck region 313f
scan 315f
technique 307
Malaria 872
Malignant hypertension 736, 808
hypertensive crisis 914
papilledema 914
Malnutrition 497
inflammation-atherosclerosis syndrome 497
Malondialdehyde 932
Mammary artery, internal 624
Marfan syndrome 216, 230
Mass index, normal 453
Massachusetts male aging study 72, 178
Massive asymmetrical hypertrophy 447f
Mastalgia 771
Maximum intensity projection 318, 368f, 569f572f, 597
McConnell's sign 389
Mean arterial blood pressure 100, 122, 188, 190, 217, 622, 793, 795, 905, 920, 932
Mechanical circulatory support 918
devices 642
systems 914
Mechanical dyssynchrony 449
Medical devices 809
Medical history 906
Medical nephrectomy 835
Medical Research Council Trial 74
Medical therapy 249
principles of 225
Membrane-stabilizing activity 697
Meningitis 872
Menopause 53
Menstrual irregularities 771
Mental pollution 61, 62
management 66
Mercury
sphygmomanometer 693
use of 693
Mesenteric ischemia 216
Metabolic abnormalities 746
Metabolic alkalosis 745
Metabolic disorder 872
Metabolic risk 129
Metabolic syndrome 88, 163, 844, 855, 857, 858, 859fc, 861, 930
clinical identification of 857t
high prevalence of 858t
pathophysiology of 858, 859fc
prevalence of 858
Methamphetamine 295, 906
Methanol 409
Methyclothiazide 409
Methyldopa 804
Methylphenidate 906
Metoclopramide test 170
Metolazone 739, 763
Metoprolol 193, 697, 699, 712, 713
Mibefradil 719
Microalbumin, urine for 134
Microalbuminuria 38, 39, 40fc, 495, 861
Microangiopathic hemolytic anemia 192
Microcalcifications 899
Microphone replaces 691
Microvascular dysfunction 391
Microvascular ischemia 375
Mid-aortic stenosis 835
Midazolam 623
Middle aortic syndrome 570
Middle-east respiratory syndrome 83
Mid-thoracic aortic obstruction 837f
Midwest pediatric nephrology consortium study 845
Migrating pain 216
Mineral and bone disorder 497
Mineralocorticoid antagonist 171, 422, 480, 768, 772, 769, 942
implications of 772
low-dose 946
role of 422
Mineralocorticoid receptor 165f, 414, 769, 770
activation pathway 120
antagonist 41, 433, 473, 491, 527, 631, 647, 942
Mineralocorticoid response element 165f
Minoxidil 804
Mirabegron 253, 822
Mitigate chronic fatigue 931
Mitral flow
spectral Doppler 339f
velocities 363
Mitral inflow, Doppler of 460f
Mitral leaflet tethering 389
Mitral regurgitation 403, 488
moderate-to-severe 383, 389
Mitral stenosis 383, 403
Mitral valve 296
M-mode of 460f
prolapse 714
Modafinil 906
Moderate-intensity continuous training 81
Molecular mechanism 905
Monoamine oxidase 252
Monocyte chemoattractant protein-1 892
Morning blood pressure surge 184, 275
Morning plasma aldosterone 907
Morphine 623
Motor vehicle crash 216
Moyamoya disease 840
Multiorgan dysfunction 917
Multiple blood pressure measurements 441
Multiple cutaneous neurofibromas 570f
Multiple endocrine neoplasia 309
Multiple lacuna infarcts 553
Multiple silent cerebral infarcts 282
Myocardial cell death 906
Myocardial contractility 869
Myocardial contraction fraction 450
Myocardial contrast echocardiography 391
Myocardial deformation 384
imaging 341f, 542
parameters 401
Myocardial disease, hypertensive 233
Myocardial dysfunction, spironolactone in 942
Myocardial enhancement 320
Myocardial fibrosis 386f, 427, 578f
Myocardial function 458
Myocardial hypertrophy 453
Myocardial infarction 25, 154, 174, 175, 175f, 185, 357, 417, 469, 509f, 609, 611, 623, 698, 728, 732, 735, 741, 795, 798, 815, 817
anterior 389
causes of 815
non-ST elevation acute 64, 609
paradox 728
risk factor for 787
risk of 267
Myocardial ischemia 216, 745
Myocardial mass 404
Myocardial microvascular dysfunction 391
Myocardial morphology imaging 320
Myocardial oxygen 817
Myocardial perfusion
assessment of 391
imaging 320
Myocardial scintigraphy 147
Myocardial sparkling 448
Myocardial strain 369, 383
analysis of 344
Myocardial tissue velocities 415
Myocardial viability, apical 391
Myocardial volume 353
Myocardium 368, 450
fibrosis of 453
segments of 369
ultrasound on 368
N
Nadolol 697
Nasal decongestants 946
National Cardiovascular Data Registry 605
National Health and Nutrition Examination Survey 39, 57, 132, 644
National Health Mission 3
National High Blood Pressure Education Program 51, 358, 692, 869
National Institute for Health 46
and Care Excellence 46, 5052
National Program for Prevention and Control
of Cancer, Diabetes, Cardiovascular Diseases and Stroke 202
of Diabetes 202
Natriuresis 784
Natriuretic peptide 25, 512, 522, 526, 527, 779, 941
based therapies 520
elevated level of 941
mechanisms of degradation of 527
system 25, 512
Natural licorice 906
Nebivolol 375, 697
Nefazodone 719
Nephrectomy, surgical 835
Nephritis, acute interstitial 495
Nephrogenic systemic fibrosis, development of 327
Nephropathy
contrast-induced 328, 610
diabetic 314, 325
Nephrosclerosis 156f
benign 156
Nephrotic disease 717
Nephrotoxic drugs 742
Neprilysin 527
endopeptidase 947
inhibitor 423, 503
Neprilysin-endothelin-converting enzyme inhibitor 781
Nesiritide 501
Neurite outgrowth inhibitor 556
Neurofibromatosis 585
Neurohormonal imbalance during stress, complex interaction of 929
Neurohumoral disorders 495
Neurohumoral factors 495, 497
Neurologic damage 793
Neurological deficit, major 216
Neutral endopeptidase 174, 175, 527
inhibitor 527
Neutrophil-to-lymphocyte ratio 146
New York Heart Association 485, 527
Newer therapies 503
Ngiotensin-converting enzyme inhibitors 491
Nicardipine 243, 793, 794
Nicotinamide adenine dinucleotide phosphate 179, 375, 718f, 721f
Nifedipine 192, 284
Night blood pressure fall 432
Night sweats 146
Nitrates 480, 817, 821, 942
Nitrendipine 713
Nitric oxide 18, 25, 73, 78, 97f, 121, 138, 139, 174, 496, 497, 550, 610, 669, 752, 769, 859, 860, 885, 891, 906
level 495
pathway, inhibition of 664
role of 859
synthase 885
Nitrites 480, 942
Nitrogen oxide 95
Nitroglycerine 193, 218, 243, 606, 794, 795
Nitroprusside 218, 243
Nocturnal blood pressure pattern, spectrum of 280
Nocturnal dipping patterns 272f
Nocturnal hypertension 270, 279, 284, 835, 948
uncontrolled 955
Nocturnal noise exposure 107
Noise pollution 106
Noncommunicable diseases 45, 202, 757, 808, 811
Noncontrast magnetic resonance 576f
angiography 576f
Nondihydropyridine 818
calcium channel blockers 171
Nondipper 275, 280
and extreme dippers 282
hypertension 348
Nonfatal myocardial infarction 163
Noninvasive blood pressure 812
Noninvasive positive pressure ventilation 481
Nonischemic cardiomyopathy 389
Nonmercury devices 693
Non-narcotic analgesics 906
Non-neurogenic causes 821
Nonpharmacologic interventions 59
Nonpharmacologic support 543
Nonpharmacological management 490, 851
Nonpharmacological treatment 41, 159
Nonrecoverable disease 921
Nonselective alpha-adrenergic antagonists 732
Nonselective alpha-blockers
adverse effects of 732
side effects of 732fc
Nonsteroidal anti-inflammatory
agents 906
drugs 16, 254, 295, 508, 802, 802b, 880, 946
Nonsteroidal dihydropyridine 772
Nonsustained ventricular tachycardia 438
Nonvalvular atrial fibrillation 796
Non-vitamin K antagonist 437, 798
oral anticoagulants, safety of 797
Nordic diltiazem 744
Norepinephrine 18, 307
Normotension 159
N-terminal pro-brain natriuretic peptide 867
N-terminal pro-B-type natriuretic peptide 941, 956
Nuclear medicine 326
Nucleus tractus solitarius 636
Nurses’ Health Study 197
Nutrition 883
O
Obese patients 692
Obesity 17, 88, 211, 276, 374, 538
and metabolic syndrome 727
Obstructive sleep apnea 27, 28, 30b, 33, 34fc, 35, 139, 276, 280, 284, 416, 433, 481, 635, 946
evaluation of 28
management for 29
pathophysiology of 28fc
prevalence of 27
syndrome 27
therapies for 31
treatment of 34
Occupational noise and hypertension 107
Occupational stress 64
Octreotide 254, 822
Ocular diseases 102
Office blood pressure 260t, 284
measurement 12, 262
Oliguria 873, 878
Olmesartan 284, 421, 744, 826f
based regimen 949
Omapatrilat cardiovascular treatment 527
Ominous fetal cardiotocography 873
Optic nerve head 100
Optic neuropathy
hypertensive 100, 102
ischemic 103
Optimal blood pressure, maintenance of 138
Oral anticoagulant 437, 798b
agents, risks of 798
Oral appliances 31
Oral contraceptive 16, 906
Oral contraceptive pill 53, 54, 142
effect of 142
Oral fast-acting nifedipine 880
Oral hypoglycemic agent 491
Oral therapy 192
Organ damage 431
chronic target 914
hypertension-mediated 276, 343, 654, 757
Organ dysfunctions, improvement of 922
Organ function, stiffness on 651t
Organ transplant 717
Organic carbon 96
Orlistat 907
Oropharyngocutaneous fistula 899
Orthostatic hypotension 47, 251, 644, 651, 781, 820, 821
drug-induced 252, 252t
management of 253fc
syndrome 650
treatment of 253
Orthostatic intolerance 820
Osmotic demyelination syndrome 745
Osmotic diuresis 956
Osmotic natriuresis 956
Osteoproximal stenosis, moderate 576f
Ostial left renal artery stenosis, severe 248f
Overnight oximetry 29
Overweight and obesity 197
Oxidant stress 25
Oxidative stress 138, 375
Oxprenolol 697
Oxygen saturation, low 507
Oxygenator and oxygenation membrane 921f
Ozone 95
P
Pacemaker 327
Pacing parameters, modifiable 943
Page kidney 585
Pain 625
abrupt onset of 216
Palpitations 914
Pancreatic insulin secretion 700
Panic syndrome 792
Papaverine 376, 377
Papillary muscles 445
Paradigm heart failure 533
trial 518, 519
Paraganglioma 16, 309, 311
Paramount trial 518
Parasternal long axis 559
Parasternal short axis 560
Parasympathetic denervation and deregulation 662
Parasympathetic ganglia 307
Parasympathetic nervous system 63
Parathyroid
adenoma 312, 313f
carcinoma 312
gland 306, 307, 312
inferior 312
hormone 891
hyperplasia 312
Paroxysmal atrial fibrillation 365
Patent ductus arteriosus 569, 569f
Patent foramen ovale 923
Peak atrial contraction strain 385
Peak atrial longitudinal strain 372
Peak systolic velocity 378, 378f, 379, 588, 590f, 591
Pediatric brain 839
Pediatric cardiology 829
Pediatric hypertension 831, 837, 844, 849
prevalence of 839
Penbutolol 697
Penile Doppler study 376
Penile fracture 379
Penile Mondor's disease 379
Penile trauma 376
Penis, ultrasonic image of 377f
Perceived exertion, rating of 80
Percutaneous coronary intervention 154, 611, 613, 816
Percutaneous transluminal
coronary angioplasty 235, 836
renal angioplasty 148
renal artery angioplasty 592
Perfusion pressure 100
Perindopril 277, 789
protection 743
Periorbital edema 313
Peripheral arterial disease 357, 722, 920
Peripheral artery 344
Peripheral artery disease 115, 296, 354, 679, 681, 798
diagnosis of 681
epidemiology of 680
management of 682
Peripheral blood pressure 288
Peripheral capillary oxygen saturation 810f
Peripheral vascular
disease 677, 731, 762, 787
resistance 19, 23, 26, 79, 865, 867
Perirenal fibrosis 585
Perivascular adipose tissue 860
layer of 860
Peroxisome proliferator-activated receptor 94
gamma 721f
Persistent albuminuria 39
Persistent hypertension despite
medical therapy 850
non-pharmacologic measures 51
Persistent pulmonary hypertension 642
Peyronie's disease 376, 379
Pharmacokinetic profile 703
Pharmacologic interventions 59
Pharmacologic therapy 171
Pharmacological treatment, refractory to 438
Pharmacotherapy 252, 471, 952
Phentolamine 193, 376, 794
Phenylpropanolamine 842
Pheochromocytoma 16, 23, 134, 192, 216, 295, 308, 309, 311, 571, 585, 793, 914, 915
induced cardiogenic 915
Phosphodiesterase 111f, 180f
type 5 379
inhibitors 75, 179, 180
Physical activity and obesity 433
Physiological diurnal variation, utilization of 664
Pickering syndrome 487
Pindolol 696, 697
Pitavastatin 717
Pituitary adenoma 311f
Pituitary disease 865
Pituitary disorder 313
Pituitary gland 306, 307
Pituitary macroadenomas 309
Placebo 75t
therapy 735, 771
Placental growth factor 870, 871, 879
Plain old balloon angioplasty 149f
Plaque formation 375
Plasma
adiponectin 99
aldosterone 166
levels 422
limitations of 166
endothelin 99
estrogen 142
leptin values 99
potassium 771
protein 771
A, pregnancy-associated 879
renin activity 166, 167, 171
Plasma-free thyroxin, measurement of 865
Plasminogen activator inhibitor 718f, 859
Platelet-lymphocyte ratio 146
Plethysmography 147
Pleural effusion 216
Polyarteritis nodosa 585, 593, 593f
Polycystic kidney disease 216, 314, 571
bilateral 315f
Polygraphy 29
Polymorphonuclear cell infiltration 900
Polysomnography 29
Pontine hemorrhage 507
Pooled cohort equation 952
Positive airway pressure 27, 33, 34
therapy 29, 30
Postangioplasty aneurysm 149
Post-Bentall procedure 216f
Post-coronary artery bypass grafting 625b
Postductal coarctation 569f
Posterior wall thickness 296
Postexercise hypotension 79, 937
Postexercise physiologic response 19
Postgadolinium scans 308
Post-heart transplant 662
Post-interventional control 598
Post-menopausal
hypertension 54
women 389
Postoperative hypertension, adverse effects of 624b
Post-percutaneous coronary intervention 620
Post-stroke 116
Post-traumatic occlusion 325
Postural orthostatic tachycardia syndrome 821
Postural stimulation test 168
Potassium 25, 412
intake
inadequate 198
low 18
sparing diuretics 417, 739, 741
Power Doppler 588
Pravastatin 717
Pre-capillary pulmonary hypertension 917, 917f
Precipitate cardiac failure 393
Pre-eclampsia 54, 692, 793, 795, 872, 878
early-onset of 870
prediction of 879
prevention of 871, 879
risk factors for 871t
treatment of 745
Pregnancy 216
use in 737
Prehypertension 15, 92, 370, 440, 831, 933
Premature cardiac disease, risk of 845
Preocclusion brachial artery dimension 141
Preoperative recipient factors 662
Preserved ejection fraction 330, 942
Pressure, end-diastolic 460f
Prevent heart attack 744
trial 743
Priapism 376, 379
Primary aldosteronism 16, 164, 169fc, 295
causes of 164
clinical applications of 163
genetic variety of 164
pathogenic mechanism of 163
subtype 168
Primary hyper-aldosteronism, classical triads of 166
Procollagen serum levels 417
Prolonged mechanical ventilation, absence of 921
Prolylcarboxyendopeptidase 174
Prolylcarboxypeptidase 174
Prolylendopeptidase 174
Prominent interscapular fat deposition 907
Promote fibrosis 453
Propranolol 75, 697
Prospective urban rural epidemiology 198
Prostacyclin 550
Prostaglandins 79, 376, 860, 869
Prosthetic mitral valves 383
Protease inhibitors 719
Protein
binding 717
kinase
C 40
G 526
mitogen-activated 175f
Protein-to-creatinine ratio 159
Proteinuria 157, 878
quantification of 159t
Proximal convoluted tubule 409, 414
Pruritus 781
Pseudoephedrine 842
Pseudoresistance 420
etiology of 802
Pseudoresistant hypertension, causes of 768b
Psychogenic stress factors 379
Pulmonary arterial hypertension 916
Pulmonary artery 917f
cannula 917f
hypertension 916
lesions of 145
low pressure receptors 898
pressure 404
systolic 369, 416, 463f, 541
to left atrium 923
Pulmonary capillary wedge pressure 359, 365, 415, 459, 663, 920
Pulmonary edema 745, 792, 873, 878
pathophysiological mechanisms of 539f
Pulmonary embolism 914
Pulmonary flow, pulse Doppler of 463f
Pulmonary hypertension 365, 485f, 488, 913, 923t
management of 642
prevalence of 404
secondary 462
Pulmonary thromboembolism 509
Pulmonary thromboendarterectomy 917
Pulmonary vascular
disease specialist 922
resistance 24f
Pulmonary veins 362
Pulse pressure 93, 689, 698
component of 394
elevated 394
widened 864
Pulse wave Doppler 586
analysis 588
Pulse wave spectral Doppler display 360f
Pulse wave velocity 139, 141, 296, 561, 860, 865
Pulseless disease, nonspecific 570
Pump
output 641
types of 641f
P-wave dispersion 303
Pyridostigmine 253
R
RAAS blockers 789
Radial strain 370
Radiation
area of 901
effect of 899, 901t
Radiofrequency catheter ablation 432
Ramipril 284, 723
Randomized controlled trials 874, 892, 933
meta-analysis of 947
Rapid eye movement 35, 280
Rauwolfia serpentina 757
Reactive anxiety disorder 901
Reactive hyperemia index 141
Reactive nitrogen species 140
Reactive oxygen species 28, 139, 550, 860, 906
generation of 138
role of 140
Receptor-neprilysin inhibitor 779
Recurrent stroke study 743
Regular echocardiography 405
Rehabilitation 927
Relative wall thickness 153
Renal angiogram 592f, 593f
Renal angiography 248
Renal artery 146, 314
anatomy 597
normal 595
aneurysm 593, 593f, 600
disease 148
dissection 593
in-stent stenosis 591
lesions 148
malignancy encircling 585
obstruction 600
revascularization 150
stenting 249, 635
role of 635
string of 592f
Renal artery stenosis 23, 148, 247, 248, 314, 591, 591t, 593, 595, 599fc
Doppler velocity indices for 588
grading of 598
left 576f, 591f
management of 248
unilateral 598f
Renal blood flow
pattern 598
reduced 742
Renal causes 808
Renal cell carcinoma 585, 600, 897
Renal damage 793
hypertension-induced 156
progression of 325
Renal denervation 160, 657
effect of 657f
endovascular catheter-based 943
therapy, current status of 657
Renal disease 156, 257, 297, 325, 802, 850
end-stage 38, 161, 265, 494, 519, 727, 731, 801
prevalence of 494
Renal dysfunction 3, 276, 496fc
advanced 327
causes of 314
early 785
Renal end-organ protection 727
Renal failure 88, 134, 210, 494, 610
acute 192, 216, 495, 795
chronic 436
end-stage 787
Renal function 26, 495
normal 328
Renal infarction 585
Renal injury 17
Renal insufficiency
chronic 873
progressive 946
Renal morbidity 691
Renal nerve
ablation 804
stimulation 660
Renal parenchyma 316f
assessment of 316f
disease 16, 295, 306, 314, 315f, 325
functional imaging of 316f
Renal protection 159
Renal replacement therapy 502
Renal sympathetic
denervation 433
nervous system 120
Renal trauma 585
Renal vascular
bed 157
compromise 306
disease 599
Renal vasculature 591
Renal vein renin assay 327
Renal vessels, external compression of 850
Renal-interlobar ratio 591
Renal-segmental ratio 590
Renin-angiotensin aldosterone axis 139
Renin-angiotensin aldosterone system 24, 26, 40, 53, 84, 92, 120, 139, 152, 154f, 173, 276, 430, 437, 480, 512, 517, 535, 585, 609, 631, 648f, 651, 657, 663, 721f, 726, 728, 739, 769, 770fc, 775, 779, 788, 821, 824, 859, 861, 865, 892, 942, 956
activation of 815
blockade 861, 874
inappropriate activity of 156
inhibitors 417, 479
pathway 120
role of 769
stimulation of 23
Renin-angiotensin system 24, 84, 120, 171t, 420, 422, 474, 496, 526, 618, 735, 801, 857, 886, 887, 891, 899, 908, 947
activation 495
cascade 174fc
Renin-responsive adenomas 171
Rennin-angiotensin systems 936
Renovascular disease 16, 50, 134, 328, 583, 585, 595, 850
clinical suspicion of 596
evaluation of 325
Renovascular hypertension 25, 314, 326t, 576, 596
causes of 585b
pathophysiology of 596
responsible for 325
screening tests for 326
testing for 326
Reperfusion strategy, selection of 816
Reserpine 742
Resistant hypertension 167, 180, 270, 420, 634, 635, 657, 748, 768, 769, 773b, 775, 776, 801, 802, 802b, 805, 808, 810, 905, 913, 914, 936, 937
aldosterone-induced fluid retention in 635
characteristics of 801
evaluation of 803, 812f
management of 422fc, 808, 908fc, 937
nonpharmacological management of 635
pathogenesis of 906fc
pharmacological treatment of 420, 421
pharmacotherapy of 769b
prognosis of 801
risk of 803
treatment of 803, 804, 907
Resistive index 379, 590
Respiratory infection 95
Restrictive-constrictive phenomenon 663
Retinal arterial occlusion 99, 103
Retinal damage 792
Retinal emboli 103
Retinal macroaneurysm 103
Retinal vascular occlusions 104f
Retinal vasculature 296
Retinal vein occlusion 99, 102, 103
Retinopathy 166
diabetic 103
grades of 101
hypertensive 99101
malignant 101
mild 101
moderate 101
Retroperitoneal masses 596
Reversible encephalopathy syndrome, posterior 321, 841
Reversible hypertension, causes of 295
Rheumatic mitral stenosis 365
Ribonucleic acid 864
virus 83
Right atrium 917
Right renal artery, chronic total occlusion of 149f
Right ventricle systolic function 404
Right ventricular
diastolic function 404
dysfunction 345
function 542
infarction 817
mechanical support 913
systolic pressure 916f
Riva-Rocci method 691
Rivaroxaban 797, 798
Road traffic noise 106
Rosuvastatin 717
Routine blood investigations 872
Routine metabolic profile 907
S
Sacubitril 520, 522, 779, 942
Sacubitril-valsartan 529
Salt intake 539
Salt reduction programs 203
Salt resistance status, diagnosis of 122
Salt restriction 543
Salt retention 156
Salt sensitive 100, 122
hypertension 119
development of 121f
management 122
mechanisms 119, 887
status 122
Salt-loading test 168
Salus's sign 100
Saquinavir 776
Scalp tingling 736
Sclerotic stage 100
Scotomas 873
Second generation axial flow pump 640f
Secondary hypertension
assessment of 322
causes of 16t, 306t, 802
endocrine cause of 307
Self-blood pressure measurement 263
Sepsis 905
Serum
adiponectin 727
aldosterone level, assessment of 167
creatinine 871
potassium and bicarbonate levels 166
uric acid 861, 871, 872
Severe acute respiratory syndrome 83
Severe respiratory failure, refractory acute 916
Sex steroids 850
Sexual dysfunction 72, 74, 75t
female 73
management of 75
prevalence of 72
SGLT inhibitors 417, 503, 783
SGLT2 inhibitor 956
and hypertension 783, 784, 955
associated decreases 956
side effects of 785
therapy 955, 956
Shock, cardiogenic 610, 918
Sibutramine 907
Siegrist streaks 102
Signal to noise ratio 597
Sildenafil 178180, 380
Simons catheter 836f
Simpson's method 461f
Simvastatin 717, 719
Single antihypertensive drugs 440
Single nucleotide polymorphisms 173
Single-photon emission computed tomography 841
Single-pill 758
combination 790, 826
antihypertensive therapy 757
Sinus
of Valsalva 560f
rhythm 430
venosus atrial septal defect 568
Sjögren's syndrome 821
Skin rashes 736
Sleep apnea 23, 841
Sleep blood pressure 268
Sleep disturbance 107
Sleep-trough mbps 277
Smooth muscle cells 717
Society for Cardiovascular Angiography and Interventions 249
Society on hypertension 748
Socioeconomic status 63, 65
Sodium 121
and magnesium levels 166
chloride 409, 802
loading leads 885
depletion, intensification of 421
diet, low 498
excretion 739
glucose
cotransporter-2 40, 283, 475
linked transporter 762
intracellular concentration of 859
nitroprusside 142, 193, 216, 794, 851
reduction 902
storage 122
Sodium-calcium exchange 906
Sodium-glucose co-transporter-2 783, 955
inhibitor 472, 620, 785
antihypertensive effects of 956b
Solid-organ transplant 832
Soluble guanylate cyclase 138
Sotalol 697
Spanish Society of Cardiology 537
Specific drug combinations 788
Speckle-tracking echocardiography 368, 370, 562
Spectral waveform patterns 588
Spinal cord injury 216
Spironolactone 414, 422, 438, 739, 741, 742, 771, 775, 776
active metabolites of 741
structure of 776f
Splenomegaly 146
Spontaneous hypokalemia 166
Stable antihypertensive therapy 955
Stable ischemic heart disease 354
Standard suprasternal notch 560
Stanford classification 215, 240, 241
Statins 341, 481, 717
antihypertensive effects of 716
mechanism of action of 716
Steady-state fast precision 577f
ST-elevation myocardial infarction 609611, 613
part of 815
Sternotomy, median 917f
Steroidal mineralocorticoid antagonist 771
Stiff aorta, role of 650t
Stiffness 25
Stop hypertension eating plan 18t
Strain echocardiography 344, 391
Strain imaging, longitudinal 453
Stress 61, 62
end-systolic 404
goal-striving 65
hormones 307
mechanism of 63fc
reduction, mindfulness-based 932
Stress-free happy life, mechanism for 68fc
Stroke 95, 163, 185, 216, 222, 344, 357, 417, 436, 507, 549, 510, 510f, 547, 551, 553, 609, 623, 669, 762, 799, 839
absolute risk of 10f
acute hemorrhagic 793
acute ischemic 793, 840
and bleeding risk stratification 508t
arterial aneurysms 25
hemorrhagic 284, 840
ischemic 549551, 840
prevention 432, 671, 699, 726
secondary 354, 551
risk factor for 787
risk of 282, 669, 670, 731
types of 670f
Structural hypertension 781
ST-segment elevation 915
myocardial infarction 64
Subclavian artery
left 315
stenosis 680
Subclinical myocardial damage 396
Subclinical systolic dysfunction 370
Subendocardial myocardial dysfunction 394
Subendocardial systolic dysfunction 349
Sudden cardiac
arrest 443, 630
death 436, 631, 818
Sudden death, risk factor for 787
Sulfamoylbenzamide class 409
Sulfonylureas 621
Sulfur dioxide 95
Superoxide dismutase 932
Supine hypertension syndrome 651
Support vector machine 329
Supramaximal antihypertensive therapy 913
Sympathetic activation, regional distribution of 88
Sympathetic ganglia 307
Sympathetic hyperactivity 87
Sympathetic inhibition 956
Sympathetic nerve 375
activity activation 495
system activity 80
inappropriate 156
Sympathetic nervous system 23, 63, 120, 495, 512, 859, 868, 784
activation of 663, 712, 739
role of 858
Sympathetic output 26
Sympathetic overactivity 265
Sympathetic stimulation 870
Sympathomimetic agents 252, 906
Symplicity catheter 943
Symptomatic cardiac disease, pre-existing 844, 845
Symptomatic carotid artery disease 671
Syncope 216
Systematic coronary risk evaluation 951
Systemic arterial
blood pressure 732
compliance 692
total 426
hypertension 426
pressure 427
Systemic disease
assessment of 101
preclinical markers of 101
Systemic hemodynamic atherothrombotic syndrome 276, 821
Systemic hypertension 33, 34, 34fc, 83, 99, 313, 318, 338, 338t, 340, 343, 345, 368, 372, 404, 443, 449f, 452, 454f, 712, 735, 752, 768
control of 840
treatment of 847
Systemic inflammatory release syndrome 903
Systemic vascular resistance 794, 869
Systolic anterior motion 448
Systolic blood pressure 9f, 11, 12, 15, 30, 46, 47, 50, 57, 63, 68, 79f, 80, 96, 115, 122, 133, 153, 163, 184, 188, 189, 190, 196, 216, 259, 267, 272f, 275, 298, 371, 389, 393, 440, 472, 507, 534, 607, 612, 623, 634, 644, 679, 689, 696, 711, 735, 736, 752, 771, 775, 801, 815, 824, 826f, 832, 932, 840, 936, 941, 948f, 951
intervention trial 47, 55, 57, 417, 671, 952
levels 283
measurement 264f
Systolic dysfunction 318, 339, 391, 448, 457, 846
Systolic function 345
Systolic Hypertension in Elderly Program 395, 418, 645, 670
Systolic longitudinal strain 453
Systolic pressure 368, 840
intervention trial 647
Systolic strain 383
T
Tachycardia, supraventricular 437
Tadalafil 179, 380
Takayasu's arteritis 146148, 150, 216, 247, 570
Takayasu's disease 145, 147, 147f, 563, 585, 592
Takotsubo cardiomyopathy 388, 389, 390f
apical 390f
etiology of 388
reverse 390f
Takotsubo syndrome 388, 714
Target organ damage 99, 103, 185, 574, 694, 861, 862, 914
evaluation 295
Telmisartan 277, 284, 722, 723
characteristics of 723b
clinical trials of 724t
effects of 723b
efficacy of 723
mechanism of action of 721f
Tetrahydrobiopterin 97f
Theophylline 31
Therapeutic efficacy 723
Therapeutic implications 283, 440
Therapeutic strategies 354
Thiazide 148, 409, 543, 618, 740, 747, 952
related hypokalemia 745
Thiazide diuretic 51, 355, 375, 409, 410, 472, 499, 618, 740, 742, 745748, 748t, 754, 762, 769, 874, 952
decrease 746
therapy 410
Thiazolidinediones 621
Thimet oligopeptidase 174
Third generation centrifugal pump 641f
Thoracic aorta
critical constriction of 150f
descending 569f, 572f
infrarenal portion of 318f
lesions of descending 145
T2-weighted images of 575f
Thoracic aortic aneurysm 224, 318, 562
Thoracic aortic transit time, echo assessment of 652f
Thoracic endovascular aortic repair 225, 231
Thoracic stent graft insertion 220t
Thoracoabdominal aorta 228
aneurysm, surgical repair of 228f
Thoracoabdominal bypass, posterior 150
Three-dimensional echocardiography 337, 400, 541, 561
Three-dimensional speckle tracking 369
Thrombocytopenia 878
Thromboembolic disease 247, 596
Thyroid
disease 295
gland 306, 307, 314f
hormonal secretion, excess of 867
hormone 864, 867
activate transcription process 864
receptor 864
peroxidase antibody 865
related ophthalmopathy 313
stimulating hormone 313, 865, 867
Thyroiditis 313
Tilt-table testing 820
Time-of-flight angiography 315, 597
Timolol 696, 697
Tinnitus 107
Tiredness 736
Tissue
characterization 597
Doppler imaging 368, 369, 370, 541
Titration study 524
Toe-brachial index 682
Tolerability 788
Tolvaptan 745
Torsemide 739, 742
Torsion 542
Total peripheral resistance 740, 859
Toxemia 878
Traditional cardiovascular disease 351
Transcapillary pressure 411
Transcendental meditation 932, 933
practice of 931
Transesophageal echocardiogram 242, 564f
Transesophageal echocardiography 560
Transesophageal three-dimensional echocardiogram 562f
Transforming growth factor beta 1 40
Transient ischemic attack 344, 621, 669671, 743, 840
Transoesophageal echocardiography 224
Transplanted renal artery, stenosis of 600
Transthoracic echocardiogram 217
Transthoracic echocardiography 224, 388, 559
Transvalvular flow rate 428
Transverse aortic arch 563f
Trauma 585
Triamterene 414, 739, 742
Trichlormethiazide 409
Tricuspid annulus plane systolic excursion 389
Tricuspid regurgitation 404, 463f
velocity 403f, 416
Tricuspid valve regurgitation 916f
Tricyclic antidepressants 821
Triglycerides 19, 831, 857
Tri-iodothyronine 865
Triple-mix test 112
Truncated ellipse 338
method 445
Tuberous sclerosis 309
Tumor necrosis factor 175f, 906
alpha 33, 139, 860, 892
Turner's syndrome 216, 847
Twenty-four-hour urinary aldosterone excretion test 168
Two-dimensional echocardiography 400, 541
Two-dimensional speckle tracking 369
U
Ulcer, atheromatous penetrating 319f
Ultrasound
abdominal 224, 326
contrast-enhanced 147
scan 586
Umbilical artery Doppler 873
Umbilicus 560f
Unhealthy diet 17
Unstable angina 192
Unstable carotid atherosclerosis 669
Upper airway obstruction, surgery for 30, 31
Uric acid 748, 861
Urinary albumin excretion rate 39
Urinary calcium excretion 746
Urinary retention 736
Urinary tract
infection 16
obstruction 495
Urine
albumin creatinine ratio 39
analysis 295
Uterine artery pulsatility index, measurement of 879
V
Valsalva maneuver 216
Valsartan 284, 421, 520, 522, 726, 779, 826f, 942, 947
antihypertensive 744
Valvular heart disease 430, 469
Vardenafil 179
Vascular calcification 497
Vascular cell adhesion molecule 1 141
Vascular circadian rhythms 276
Vascular disease 92, 508
Vascular endothelial
cell inflammation 485
growth factor 40, 870
Vascular endothelium 891
Vascular end-stage disease 38
Vascular function 129, 860
Vascular inflammation 94
Vascular surgery 150
Vasculitis 585, 596
active 147
Vasculopathy 840
Vasoactive substances 379
Vasoconstrictive stage 100
Vasodilator 218, 500, 897
mediators 885
Vasogenic edema 321f
Vasomotor center 897
Vasopressin analogs 253
Vasopressin receptor antagonist 502
Velocity-sensitive flow-dependent 597
Vena cava, superior 920
Venography 327
Veno-occlusive disorder 376
Venous occlusion plethysmography 140
Venous thrombosis 376
Ventricular activation time 302, 303f
Ventricular arrhythmias 436, 437
Ventricular assist device 913
Ventricular fibrillation 63
Ventricular hypertrophy 174
Ventricular matrix formation 485
Ventricular premature beats 630
Ventricular septal defect 568
Ventricular strain measurements 384t
Ventricular tachycardia 436, 453
Venular tortuosity 101
Verapamil 699, 746
Vessel
abdominal 899
reactivity 25
Viagra 179
Visceral adiposity 858
Visual blurring 873
Visual disturbances 878
Vitals monitoring 880
Vitamin
D
deficiency 890, 891fc
effect of 891
modulates toll-like receptor 892
receptors 891
role of 890
K antagonists 796
Volume reflex 899
Volume-rendered techniques 567
von Hippel-Lindau disease 309
von Recklinghausen neurofibromatosis 309
W
Wall motion abnormality 388
Warfarin 798, 799
Water-based exercise 937
Wave intensity analysis 579
Weight loss 146, 199, 499, 803
Western guidelines 953
Whickham survey 865
White blood 320
White-coat effect 907
White-coat hypertension 101, 103, 127, 128f, 129, 129f, 159, 260, 262, 265, 269, 269f, 294, 654, 691, 832, 849, 901, 946
diagnosis of 951
prevalence of 263
Windkessel function 223
World Health Organization 8, 11, 72, 83, 158, 196, 469, 885
Worsening disease, features of 880
X
Xalmodulin-dependent protein 475
Y
Yoga 931, 931t, 933t
benefits of 933
in heart disease, psychophysiology of 930fc
mechanism of 929
role of 929
Yohimbine 380
Z
Zona glomerulosa cells 165
×
Chapter Notes

Save Clear


1Clinical
  1. Current Challenges and Future Directions in the Clinical Management of Hypertension
  2. Controversies to Consensus in Hypertension Classification and their Impact
  3. Risk Factors Responsible for Hypertension
  4. Pathophysiology of Hypertension
  5. OSA and Hypertension: Present Status and Future Directions
  6. Obstructive Sleep Apnea and Systemic Hypertension
  7. Microalbuminuria, Hypertension and Diabetes Mellitus: A Triple Jeopardy
  8. Hypertension in Elderly Diabetics: Management Strategies
  9. Hypertension in Young: Management Strategies
  10. Hypertension in Women: Is it different?
  11. Hypertension in Elderly in what Way Management is Different
  12. Stress, Mental Pollution and Hypertension
  13. Sex and Hypertension: Myth and Facts
  14. Exercise and Hypertension
  15. COVID-19 and Systemic Hypertension
  16. The Role of Autonomic Nervous System in Hypertension
  17. Vascular Disease and Hypertension
  18. Air Pollution and Hypertension
  19. Eye and Hypertension: Changing Perspectives
  20. Noise Pollution and Hypertension
  21. Does Hypertension and its Pharmacotherapy Affect the Quality of Sexual Function?
  22. Reduction of BP Targets to Reduce CVD Events: Status 2020 and Beyond
  23. Salt Sensitive Hypertension: Emerging Insights in an Old Entity
  24. White Coat Hypertension: Clinical Outcome
  25. Critical Appraisal of Essential Hypertension in Young Adults
  26. Hypertension and Endothelial Dysfunction
  27. Hypertension and Aortoarteritis
  28. Hypertension and Left Ventricular Hypertrophy: Clinical Implications
  29. Hypertension and CKD: A Double Jeopardy
  30. Hypertension and Conn's Syndrome: Management Strategies
  31. Renin–Angiotensin–Aldosterone System 2020
  32. Hypertension and Sildenafil
  33. Hypertension, Seasonal, Diurnal BP Variability and CVD Risk
  34. The Management of Hypertension during the Perioperative Period
  35. Hypertension Preventive Strategies and Campaign in India
  36. Hypertension with Multiple Comorbidities
  37. Aortic Dissection in Hypertension: Management Strategies
  38. Long-term Cardiovascular Sequelae of Uncontrolled Hypertension and their Surgical Management
  39. Hypertension with Arterial Dissections: A Jeopardy
  40. Hypertension with Renal Artery Stenosis: Management Strategies
  41. Orthostatic Hypotension in Hypertensives Patients: Management Strategies2

Current Challenges and Future Directions in the Clinical Management of HypertensionCHAPTER 1

Shivam Dutt,
Rohit Tandon,
Bhupinder Singh,
GS Wander
 
INTRODUCTION
Hypertension is the most prevalence disease in India. It causes significant burden on the health system. According to data from the global burden of disease (GBD) study of 2016, hypertension led to 1.63 million deaths in India in the year 2016 alone.1 A population-based cross sectional study carried between 2012 and 2014 with the sample size of 1.3 million estimates the prevalence and hypertension in India at around 26%.2 GBD data also showed that over half of the deaths due to ischemic heart disease (54.2%), stroke (56.2%) and chronic kidney disease (54.5%) were attributable to high systolic blood pressure (BP).2 The prevalence is expected to much higher as hypertension is a silent disease and the most of the individuals are not even aware of their BP status. Moreover control of hypertension requires strict adhesion to the therapy with regular BP measurements. In a meta-analysis it was found that only 25% of rural and 42% of urban population are aware about BP status3 and even less followed up after elevated BP reading.
Patients with hypertension should be classified in the following manner:
Grade 1 hypertension
Systolic 140–159 mm Hg and/or diastolic 90–99 mm Hg
Grade 2 hypertension
Systolic 160–179 mm Hg and/or diastolic 100–109 mm Hg
Grade 3 hypertension
Systolic 180 mm Hg or above and/or diastolic 110 mm Hg or above
Isolated systolic hypertension
Systolic >140 mm Hg but diastolic <90 mm Hg
Source: Adapted from the Eighth Joint National Committee, 2014.
Two other terminologies frequently used are:
  1. Hypertensive urgency—severe asymptomatic hypertension (usually systolic >180 mm Hg and diastolic >120 mm Hg)
  2. Hypertensive emergency—severe hypertension accompanied by cardiac (e.g., acute left ventricular failure), neurological (e.g., hypertensive encephalopathy), or renal dysfunction.
 
WHAT HAVE WE DONE?
As a response to the low awareness levels, the Government of India launched the universal screening program for hypertension, diabetes mellitus, and three common cancers (breast, cervix, and oral cancer) in 2017 under the National Health Mission (NHM).4 Under the program, the auxiliary nurse midwife (ANM) and accredited social health activist (ASHA) are responsible for organizing screening activities at the villages and other subcenters. All the individuals with the BP > 140/90 mm Hg are referred to a medical officer for conformation and further evaluation. In a similar effort, over the last 2 years, the International Society of Hypertension in conjunction with the World Hypertension League has been implementing the “May Measurement Month”—a global awareness campaign that aims to improve access to screening of BP.5 The theme of 2019 World Hypertension Day was “Know Your Numbers” and focuses on the importance of screening for early detection and treatment of hypertension.6 The main focus of guidelines on hypertension is early detection through screening and a strong public awareness program educating individuals and the harmful effects of this silent disease. A public health 4approach to hypertension in India would involve the five components detailed below. This includes five population level interventions for prevention of hypertension of which reduction of obesity, salt intake, and cessation of tobacco use are the most important; screening of the adult population at five points of care for hypertension by trained staff using standardized BP measurement with validated devices, and management of hypertension with lifestyle modifications combined with therapy using representative drugs from five classes of antihypertensive, which should be made available in the public health system.
 
UNIVERSAL SCREENING AND CHALLENGES IN ITS IMPLEMENTATION
As Kaplan mentioned in the Joint National Committee in 1998, BP measurement is the “clinical procedure of greatest importance that is performed in the sloppiest manner.”7 The rationale behind the government-led universal screening program has been improving equity and awareness within the underprivileged strata of society by giving them access to quality health care also raising awareness against the risk factor commonly associated with hypertension. Also the benefit of screening outweighs its harm as recommended by US Preventive Services Task Force recommendation statement. Screening is the most powerful and effective method in combating hypertension. The operational guidelines state that screening is to be conducted at the community level so that no individual has to travel for more than half an hour in order to be screened8 leading to important reduction in peak work output. According to the NHM document, the program also aims to improve overall awareness regarding noncommunicable diseases and risk factors through increased information, education, and communication activities.8 All adults above the age of 18 years should undergo opportunistic screening by healthcare providers at all points of care in India, either during the course of their visits to the health facilities, or separately as a screening examination if requested by the person. Targeted screening at the community level of high-risk groups like the elderly (>60 years), obese, current smokers, those with diabetes, those with existing cardiovascular disease, and those with a strong family history of heart disease or stroke can be undertaken by trained nonphysician staff. This screening will also enable people with high BP to be identified, so that they can be prevented from developing hypertension by use of appropriate lifestyle modifications. High-risk individuals including people with age >50 years, those who are obese, diabetic, current smokers, those who have history of any cardiovascular disease (coronary artery diseases, stroke, etc.), or a history of hypertension or premature cardiovascular disease in the family can be recognized and managed accordingly.
But screening such a last populations requires enormous amount of manpower, training, and resources and already the government-run program is behind its target for 2018–19.9 So the question is—“Is screening the most beneficial method for resource-limited setting in India? Moreover ASHA/ANM workers have other responsibilities in addition to this and doing this on an annual basic requires a lot more work. Improper BP measurement can lead to higher BP measurement and overestimation of individual true BP and lead to inaccurate classification. This in turn increases the burden on the healthcare system. In a study done by Jose AP et al. on 678,490 individuals, the impact of repeated BP measurements on BP categorization was done and it was observed that there was 63% higher prevalence of hypertension when only first BP measurements were considered for diagnosis compared to mean of second and third reading.10 Healthcare professionals (HCPs) are yet to master the technique that was invented 100 years ago. This means that a significant population is being wrongly diagnosed and is subjected to unnecessary treatment. On the other hand, underestimation of BP can be missed opportunity for starting lifestyle changes and pharmacotherapy and also carries ethical implications. Aware of the outcomes of ill-advised screening method, guarantee that the preparation of ASHAs, ANMs, and clinical officials is completed with tirelessness and caught up with fresh training at regular interval.
Table 1 lists the sources of errors produce a false BP measurement.
TABLE 1   Sources of measurement error with comments.
Sources of measurement error
Comment
Back is not supported
Diastolic BP may increase by 6 mm Hg
Arm is not at level of heart
Dangling the hand unsupported increases BP by 10–12 mm Hg
Legs are crossed
Systolic BP increases by 2–8 mm Hg
Caffeine in the last 1 hour
Transient increase in BP
Smoking in the previous half an hour
Transient increase in BP
Cuff size not appropriate
May overestimate systolic BP by 10–50 mm Hg in obese persons in whom a smaller cuff has been used
Rapid deflation >3 mm/sec
May underestimate systolic BP and overestimate diastolic BP
Patient's anxiety/conditional response to an unusual situation in the presence of a physician
This may result in elevated BP readings, which may be normal when recorded by a nurse or when recorded at home. This “white coat hypertension” or “isolated office hypertension” may constitute 32% of hypertensive subjects in four population based surveys
Source: Adapted from Standard Treatment Guidelines. Ministry of Health and Family Welfare Government of India.
5
 
USE OF DIGITAL (OSCILLOMETRIC) DEVICES
In evidence-based systematic review, oscillometric devices were considered appropriate for use in adults (Level A recommendation) including for those with trauma and shock, and were given a Level B recommendation for use in adults with hypertension, because of discrepancies accruing from increased arterial stiffness. However, other studies have cited concerns about their accuracy.11 In a study of validated digital devices in practice settings, 88% of digital devices had measurement within 3 mm Hg of the reference standard compared to 95% of mercury sphygmomanometers, suggesting that digital devices can have accuracy equivalent to mercury sphygmomanometers.12 The World Health Organization (WHO) recommends the use of electronic devices, which are affordable and reliable and which have the capacity for manual settings.13 Although the cost of digital devices might be more than the manual devices but using digital device can also decrease the need of trained staff in an already resource-limited country thereby cutting cost.
 
ROLE OF AYUSH DOCTORS
As per WHO in 2016 there were 1,225,381 health workers in urban areas and 844,159 in rural areas, an urban–rural ratio was 1.45. Of all health workers, 59.2% were in urban areas, where 27.8% of the population resides, and 40.8% were in rural areas, where 72.2% of the population resides. The ratio of urban density to rural density for doctors was 3.8 (Fig. 1).
AYUSH is an acronym for Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homeopathy and are the six Indian systems of medicine prevalent and practiced in India and some of the neighboring Asian countries with very few exceptions in some of the developed countries. National Rural Health Mission came into play in 2005 but implemented at ground level in 2006 and introduced the concept of “mainstreaming of AYUSH and revitalization of local health traditions” to strengthen public health services.7,14 This concept helped in utilizing the untapped AYUSH workforce, therapeutics, and the principles for the management of community health problems at different levels. This convergence has been envisaged with the following objectives:
  • Choice of the treatment system to the patients
  • Strengthen facility functionally
  • Strengthen implementation of national health programs7,14,15
Lately, the government has been actively promoting AYUSH and one of the main functions of AYSUH is to help with National Health Policy. India's allopathic doctor–patient ratio is at 1:1445, lower than the WHO's norm of 1 doctor per 1,000 people, and with this vast deficit we need health workers for such mass screening programs.
Various hindrances exist at different degrees of the healthcare cascade that account for the low rates of BP control in India. At the health system level, a low political priority is given to hypertension. At a hospital level, poor healthcare provider education in hypertension management, the lack of a systematic approach and inadequate access to drugs serve to undermine BP control.
zoom view
Fig. 1: Health workers by category: absolute number.Source: Adapted from the Health Workforce In India. WHO; 2016.
6At a community or individual level, lack of awareness of hypertension, limited capacity to bear out of pocket costs, and competing life priorities make control of BP challenging.11
There are certain essential steps that are needs to be taken for control hypertension. A model system that is universal in all of India needs to be setup that includes:
  1. Measuring BP in hospitals in systematic standardized methods at every hospital visit while educating all concerned healthcare workers in its correct measurement.
  2. Informing each patient of its BP goals, current BP, and reminding him the importance of taking prescribed drug for the same.
  3. Including the nonphysician healthcare staff in managing HCP and educating people against diagnosis and follow up.
  4. A closed pharmacy system that provides hypertension drugs at below typical market prices through bulk purchases.
REFERENCES
  1. Gakidou E, Afshin A, Abajobir AA, Abate KH, Abbafati C, Abbas KM, et al. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease study 2016. Lancet. 2017;390:1345–422.
  1. Geldsetzer P, Manne-Goehler J, Theilmann M, Davies JI, Awasthi A, Vollmer S, et al. Diabetes and hypertension in India: a nationally representative study of 1.3 million adults. JAMA Intern Med. 2018;178:363–72.
  1. Anchala R, Kannuri NK, Pant H, Khan H, Franco OH, Angelantonio DE, et al. Hypertension in India: a systematic review and meta-analysis of prevalence, awareness, and control of hypertension. 2014;32(6):1170–7.
  1. Shri JP (2017). Nadda inaugurates National Training for Universal Screening and Control of Common NCDs. [online] Available from: http://pib.nic.in/newsite/PrintRelease.aspx?relid=161821 [Last accessed October, 2020].
  1. May Measurement Month. [online] Available from: http://maymeasure.com/ [Last accessed October, 2020].
  1. International Society of Hypertension. May Measurement Month & WHD. [online] Available from: http://ish-world.com/public/world-hypertension-day.htm [Last accessed October, 2020].
  1. New Delhi: Government of India;  2005. Ministry of Health and Family Welfare. National Rural Health Mission (2005–2012), Mission document.
  1. National Health Mission, Ministry of Health & Family Welfare, Government of India. Operational Guidelines-Prevention, screening and control of common non-communicable diseases: Hypertension, diabetes and common cancers (oral, breast, cervix). [online] Available from: http://nicpr.res.in/images/PDF/guidelines_for_population_level_screening_of_common_NCDs.pdf [Last accessed October, 2020].
  1. 2.3 crore screened for BP, cancers in 1 year under Modicare. [online] Available from: https://timesofindia.indiatimes.com/india/over-1-3-crore-screened-for-bp-cancers-in-1-year-undermodicare/articleshow.
  1. Jose AP, Awasthi A, Kondal D, Kapoor M, Roy A, Prabhakaran D. Review Impact of repeated blood pressure measurement on blood pressure categorization in a population-based study from India. J Hum Hypertens. 2019;33(8):594–601.
  1. Skirton H, Chamberlain W, Lawson C, Ryan H, Young E. A systematic review of variability and reliability of manual and automated blood pressure readings. J Clin Nurs. 2011;20(5-6):602–14.
  1. A'Court C, Stevens R, Sanders S, Ward A, McManus R, Heneghan C. Type and accuracy of sphygmomanometers in primary care: a cross-sectional observational study. Br J Gen Pract. 2011;61(590):e598–603.
  1. Parati G, Mendis S, Abegunde D, Asmar R, Mieke S, Murray A, et al. Recommendations for blood pressure measuring devices for office/clinic use in low resource settings. Blood Press Monit. 2005;10(1):3–10.
  1. New Delhi: Ministry of Health and Family Welfare, Government of India;  2005. National Rural Health Mission. Framework of Implementation; 2005–2012.
  1. New Delhi: Ministry of Health and Family Welfare, Government of India;  2011. National Health System Resource Center. National Rural Health Mission, Mainstreaming of AYUSH and Revitalization of Local Health Traditions under NRHM, An Appraisal of the Annual State Programme Implementation Plans 2007–2010 and Mapping of Technical Assistance Needs.